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Regio- and stereoselective hydroxylation is a very useful and important reaction 
in green chemistry as well as in chemical and pharmaceutical synthesis. Despite 
of some progresses, this type of reaction remains as a challenge for classic 
chemistry. Alternatively, nature provides with a useful solution for this reaction 
by using monooxygenases as catalysts and molecular oxygen as a cheap and 
green oxidant. However, there are still several problems that limit the practical 
application of monooxygenases, such as narrow substrate scope and unsatisfied 
activity and selectivity toward a given non-natural substrate. Previously, our 
group discovered a novel P450pyr monooxygenase from Sphingomonas sp. 
HXN-200 as a unique catalyst for biohydroxylation with great potential for 
pharmaceutical and fine chemical synthesis. In this thesis, we successfully 
engineered this P450pyr monooxygenase for the highly regio- and 
enantioselective subterminal hydroxylation of alkanes, an easily available and 
abundant feedstock. We started with the development of a powerful regio- and 
enantioselective colorimetric high-throughput screening (HTS) assay. Three 
alcohol dehydrogenases, CpSADH, PfODH, and YAD, which are highly 
specific for the oxidation of (S)-2-octanol, (R)-2-octanol, and 1-octanol, 
respectively, were identified and used in three parallel experiments to oxidise 
the product mixture from biohydroxylation of n-octane. The concentrations of 
produced alcohols were determined by NBT-PMS assay, and therefore allowed 
quick identification of mutants with improved regio- and enantioselectivity by 
comparing the ratio of absorbance against that of the parental enzyme. Based 
on the n-octane-P450pyr docking model, 22 amino acids residues within 6 Å of 
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n-octane, in the substrate access channel, and in the “big loop” were chosen for 
iterative saturation mutagenesis(ISM). After six rounds of evolution, several 
P450pyr mutants with enhanced regio- and enantioselectivity were obtained. 
One sextuple mutant, P450pyrSM1, showed >99% subterminal selectivity and 
98% (S)-enantioselectivity for the hydroxylation of n-octane; whereas the 
P450pyr only gave 1-octanol due to its terminal selectivity. With a Km of 2.187 
mM and a kcat of 5.9 min-1, this P450pyrSM1 showed nearly the same catalytic 
efficiency (kcat/Km) for the subterminal hydroxylation as that of P450pyr for the 
terminal hydroxylation. This engineered P450pyr is the first enzyme for this 
type of highly selective alkane hydroxylation, and the generation of 
P450pyrSM1 in this study is the first successful example of the full alteration 
of enzyme regioselectivity and simultaneous establishment of high 
enantioselectivity for biohydroxylation by directed evolution.  
P450pyr monooxygenase showed excellent terminal hydroxylation toward 
hydrophobic substrates such as alkanes, but no activity towards hydrophilic 
molecules such as alcohols. In order to extend its substrate range, we then 
engineered this P450pyr monooxygenase for the terminal hydroxylation of n-
butanol to produce 1,4-butanediol, a useful chemical in polymer synthesis and 
chemical production. So far, no chemical- or biocatalyst was reported for this 
reaction. We started with the development of a colorimetric HTS assay for 
directed evolution by using 2-methoxyethanol, which is structurally similar to 
n-butanol, as a surrogate substrate. Terminal hydroxylation of 2-
methoxyethanol generated an unstable diol which would decompose to ethylene 
glycol and formaldehyde. The amount of formaldehyde was measured at 550 
nm by adding purpald to give a purple compound. All the positive mutants 
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selected by using the surrogate substrate-based HTS assay were further 
examined for biohydroxylation of n-butanol. In the two rounds of evolution, 
P450pyr single mutant I83M and double mutant I83M/I82T were found to show 
excellent terminal regioselectivity for the hydroxylation of n-butanol, with 
relatively high activity and no by-product formation. This gives a unique 
example of engineering a hydroxylase to accept a hydrophilic substrate from the 
original preference of a hydrophobic substrate by directed evolution.  
Finally, we explored the synthetic potential of all the engineered P450pyr 
variants generated by directed evolution for the hydroxylation of fluoro- and 
other halo-substituted toluenes to produce benzyl alcohols, which are important 
and widely used intermediates for the productions of pharmaceuticals, fine 
chemicals, and agrochemicals. A P450pyr triple mutant, named as P450pyr3M, 
was discovered as the first enzyme with excellent activity and chemo- and 
regioselective for the benzylic hydroxylation of single and multiple fluoro-
substituted toluenes. This enzyme also showed a broad substrate range, high 
activity and high conversion for the hydroxylation of chloro- and bromo-
toluenes. These hydroxylations provided a simple access to the corresponding 
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 Chapter 1: Introduction 
1.1 Green Chemistry  
Chemistry is a key scientific discipline which has a great impact on everyone's 
daily life. It is estimated that in 2010 the chemical industry contributes about 
US$ 4900 billion sales worldwide and 7.7 % of the world gross domestic 
product (GDP), within which approximately US$ 875 billion sales are come 
from pharmaceuticals.1 It has been widely acknowledged that the big impact of 
chemistry calls for responsibility. In order to implement the sustainable 
development in chemical and pharmaceutical industry, the term of “Green 
Chemistry” was first used at the beginning of the 1990s.2 After that, similar 
concepts such as “Atom Economy” and “E Factor” were developed.3 In 1998, 
Anastas and Warner introduced the “Twelve Principles of Green Chemistry”: 
Prevention; Atom Economy; Less Hazardous Chemical Syntheses; Designing 
Safer Chemicals; Safer Solvents and Auxiliaries; Design for Energy Efficiency; 
Use of Renewable Feedstocks; Reduce Derivatives; Catalysis; Design for 
Degradation; Real-time analysis for Pollution Prevention; Inherently Safer 
Chemistry for Accident Prevention.4 Since then, the concepts and principles of 
Green Chemistry have been international recognised and adopted by chemists 
to design and develop new products, processes and services that use less toxic 
and inherently safer chemicals, as well as alternative reaction conditions and 
solvents for improved selectivity and/or energy minimisation. The rapidly 
growing interest in green chemistry is partly witnessed by the establishment of 
the US Presidential Green Chemistry Challenge Awards in 1995, the foundation 
of Green Chemistry Institute in 1997, the publication of the ﬁrst volume of the 
2 
 
Green Chemistry journal in 1999, and the growth of Green Chemistry relevant 
conferences and events be held in the USA, Europe and Asia.5,6 
Although many new greener products and processes have been developed over 
the last 20 years, there are still various challenges ahead. Currently, many 
important pharmaceutical synthesis processes are no longer acceptable or still 
not green enough in the Green Chemistry conscious era.  In 2005, the ACS 
Green Chemistry Institute (GCI) and seven global pharmaceutical companies 
(including: AstraZeneca, Eli Lilly, GSK, Johnson & Johnson, Merck, Pfizer, 
and Schering–Plough) organised a roundtable conference to develop a list of 
key research areas for future improvement.7 One of the highlighted key 




Biocatalysis refers to the use of natural catalysts such as enzymes to perform 
complex chemical reactions of organic molecules.8 It is a major part of 
biotechnology, which offers a sustainable production of food (e.g., bread, 
cheese, beer, vinegar), fine chemicals (e.g., amino acids, vitamins), and 
pharmaceuticals to meet various human needs.9 Over the last 20 years, 
increasing interest has been generated in biocatalysis mainly because it is a 
greener and more environmental friendly approach with reduced energy 
consumption, waste generation and greenhouse gas emission.10 Most of the 
biocatalytic processes are well aligned with the twelve principles of Green 
Chemistry (Table 1.1).11  
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Table 1.1 Green Chemistry vs Biocatalysis11 
Green Chemistry Principle Biocatalysis 
1. Prevention  
Enables more sustainable routes to APIs 
effectively reducing level of waste. 
2. Atom economy Enables more efficient synthetic routes. 
3. Less hazardous chemical syntheses Generally low toxicity. 
4. Designing safer chemicals No impact. 
5. Safer solvents and auxiliaries 
Often performed in water; when solvents are 
used they are generally Class I or II. 
6. Design for energy efficiency 
Usually performed slightly above room 
temperature. 
7. Use of renewable feedstocks Renewable. 
8. Reduce derivatives  
Chemo-, regio-, enantioselective enzymes 
obviates need for protecting groups. 
9. Catalysis  Catalytic. 
10. Design for degradation  No impact. 
11. Real-time analysis for pollution 
prevention 
No impact. 
12. Inherently safer chemistry for accident 
prevention 
Generally performed under mild conditions 
where risk of explosions is minimal. 
 
Although the word “biocatalysis” is relatively new, but the concept has been 
utilised in practice for thousands of years in the production of beer, wine, 
vinegar, yoghurt and cheese.12 The Egyptians and Babylonians produced 
alcoholic beverages from barley since 800 BC and the early Christian and 
Sanskrit writings described fermented dairy products.13 However, throughout 
the centuries no one really knew that biocatalysts were involved in these 
processes. With the advent of the pharmaceutical industry, since 1940s 
biocatalysts have been widely used in the production of antibiotics (e.g., 
penicillin).14 Over the past decades, major advances in microbiology and 
molecular biology have increased the range of available biocatalysts and their 
applications.8,15,16 In particular, the development of protein engineering, 
including rational design and directed evolution, has enabled scientists to 
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effectively modify the properties of biocatalysts for targeted chemical 
reactions.17-23 In the present day era, almost all the enzyme properties, including 
stability,24-26 activity,27-29 selectivity,30-32 and substrate speciﬁcity 33-35 could be 
engineered routinely in the laboratory.  
According to a recent business report from BBC Research, the global market 
for industrial enzymes is about US$ 3.3 billion in 2010. This market is expected 
to reach US$ 4.4 billion by 2015 with an annual growth rate of 6 %.11 The use 
of lipases, esterases, and proteases is now widely established throughout 
industry. It is estimated that currently more than 130 different biocatalytic 
processes are applied in chemical, pharmaceutical, agricultural, and food 
industries.36,37 
Other types of enzymes, such as oxynitrilases, aldolases, alcohol oxidases, 
alcohol dehydrogenases, nitrilases and cytochrome P450 monooxygenases, are 
starting to become more and more recognised and some of them have already 
been commercially available. Two particular groups of enzymes that have seen 
growing interest and demand are alcohol dehydrogenases for asymmetric 
ketone reduction to chiral alcohols; and P450 monooxygenases for selective 
hydroxylation of desired molecules.11 
1.2.1 Advantages and Disadvantages of Biocatalysis vs. Chemical 
Catalysis 
Similar to chemical catalysis, biocatalysis provides an alternative pathway for 
the conversion of the substrates to the products, in which less free energy is 
required to reach the transition state.38 Nevertheless, biocatalysis offer several 
special characteristics over chemical catalysis.  
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The biggest and most important advantage of biocatalysis is its unsurpassed 
selectivity.39 This selectivity is often functional (chemoselectivity), positional 
(regioselectivity) and chiral (enantioselectivity) specific.40 There are numerous 
successful examples have shown that >99 % of a desired selectivity could be 
achieved routinely by using biocatalysis,41 and in many cases >99 % of two or 
even three selectivities could be reached simultaneously.42 This high selectivity 
becomes increasingly important, useful and desirable in the chemical and 
pharmaceutical industries, as it could offer numerous beneﬁts including reduced 
protection/deprotection steps, minimised side reactions and by-products, easier 
downstream purification and separations; as well as much fewer environmental 
problems.10,37  
Other advantages of biocatalysis, such as high catalytic activity, working in 
aqueous medium, and high active at mild reaction conditions, ambient 
temperature and atmospheric pressure are also attractive. Since all these benefits 
are in line with the goals and requirements for modern industrial processing 
including “Green Chemistry”, “Sustainable Development”, as well as 
“Environmentally Benign Manufacturing”.43,44 
Compared with chemical catalysis, insufficient stability in a desired media, 
limited biocatalysts available for the desired reactions, and serious substrate or 
product inhibition are the three major drawbacks of biocatalysts.39 However, all 
these weaknesses are mainly due to a lack of a detailed understanding of the 
biocatalysis, or advances in biocatalysis have been improved steadily. Just about 
twenty years ago, only a few biocatalysts were commercially available, however 
in the present day, this number has increased more than a few hundred-fold.8 
Many of these commercially used enzymes show excellent stability with half-
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lives of days, months or even years,45 and some of them can also accept non-
natural substrates and convert them into wanted products.46,47 Besides, by using 
immobilisation technology, the stability of biocatalysts in the reaction mixture 
could be significantly improved and the separation of biocatalyst from products 
becomes easier at the same time.48-50 In addition, thanks to the rapid advances 
in genetic engineering, all of the biocatalyst characteristics, in theory, could be 
tailored with rational design, directed evolution and metabolic engineering 
methods to meet any specific reaction criteria. 
 
1.3 Regio- and Enantioselective Hydroxylation 
Saturated hydrocarbons, such as alkanes from natural gas and crude oil, are 
among the world’s most abundant and cheapest feedstocks.51 Currently, 
hydrocarbons are mainly used as an energy source and their potential as raw 
materials to be transformed into more important and valuable chemicals is 
underutilised. This is because the C-C bonds and C-H bonds in saturated 
hydrocarbons are energetically stable and usually resistant to reactions with 
acids and bases.52  
The advances of direct activation and functionalisation of the C-H bonds could 
lead to new paradigms in material and energy technologies that are more 
efficient and environmental friendly. Among them, the development of regio- 
and stereoselective hydroxylation is of particular interest, from both scientific 
and economic viewpoints.53,54 Octane, for example, is one of the main 
constituents of petroleum and gasoline and could be considered as one of the 
cheapest raw materials in the world.55 However, its subterminal hydroxylation 
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product, 2-octanol, is a valuable chemical reagent and useful substrate and 
intermediate for several industrial processes.56-61 Besides, since this selective 
hydroxylation allows a functional group to be added directly at an inactive 
position, it is especially useful and applicable in the pharmaceutical synthesis, 
in which usually multi-steps are involved.62  
Although the regio- and stereoselective hydroxylation is a very important and 
useful reaction for chemical industry, there are three main drawbacks in the 
current technologies: 63-67 First, harsh conditions and high temperatures are 
required; Second, the reactivity for the functionalisation of C-H bonds is 
insufficient; last but not least, the by-products are corrosive. Therefore the 
development of novel catalyst, which allows regio- and enantioselective 
hydroxylation of saturated C-H bond at room temperature, with high yield and 
few steps, would be particularly important, necessary and interesting.  
1.3.1 Regio- and Enantioselective Hydroxylation with Chemical 
Catalysis 
Fundamentally, the hydroxylation is an oxidative process that involves 
conversion of a C-H group to a C-OH group of an organic compound. During 
the past two decades, the development of selective chemical catalysts for the 
regio- and enantioselective hydroxylation has attracted growing interests 
amongst synthetic chemists. Many homogenous hydroxylations have been 
reported.68-70 Within them, the rapid development of metal-complex catalysts is 
considered as one of the most promising directions.71 Besides, in contrast to 
other presently processes, most metal-complexes catalysed reactions could 




Figure 1.1 Examples of reported C-H activation with metal-complex catalysts.72-75 
 
Despite these achievements, only few examples of metal-complex catalysed 
hydroxylation have been applied in industry since the yield and selectivity are 
still unsatisfied. To date, regio- and enantioselective hydroxylation remains a 
great challenge for classic chemistry. Generally, there are two reasons for the 
poor performance of metal-complex based reactions. First, the regioselectivity 
and stereoselectivity are difficult to control. There is almost no difference in 
reactivity between various C-C and C-H bonds in the saturated hydrocarbons. 
Therefore it is very difficult to design a chemical catalyst which could 
hydroxylate a desired C-H bond with specific enantioselectivity.76 Second, the 
chemoselectivity is also difficult to control. In the methane oxidation process, 
for example, the C-H bond in methanol is about 11 kcal/mol weaker than that 
in methane, which implies that methanol is a better substrate for the further 
oxidation as compared to methane,.77,78 Therefore, the alkane hydroxylation 
product usually is a mixture of alcohols, aldehydes, ketones and carboxylic 
acids.79   
1.3.2 Regio- and Enantioselective Hydroxylation with Biocatalysis 
Although regio- and enantioselective oxidation of C–H to C–OH is a significant 
challenge for chemical catalysis, but with biocatalysis this reaction is often 
proceeded in a simple one-step synthesis. By using this approach, so far a large 
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number of organic substrates have been converted to valuable products such as 
pharmaceuticals, flavors and fragrances and fine chemicals.8,80 In biocatalysis, 
generally this type of reaction is catalysed via monooxygenases.81-84 
Monooxygenase is a sub-class of oxidoreductases which are able to insert an 
oxygen atom into a C-H bond by receiving an electron from NAD(P)H; while 
only H2O is produced as a by-product (Figure 1.2). The necessary oxygen atom 
comes from molecular oxygen, which is a cheap and environmental friendly 
oxidant. This biohydroxylation is often highly regio- and enantioselective, 
which is strongly necessary for the chemical and pharmaceutical industry.85,86 
 
 
Figure 1.2 Hydroxylation reaction catalysed by monooxygenase 
 
Some monooxygenases have been extensively studied including methane 
monooxygenases (MMO),87-89 alkane monooxygenases (alkB)90-92 and 
cytochrome P450 monooxygenases (P450cam,93-95 P450BM-3,96-101 and 
P450pyr42,102-104). While the MMO only catalyse short-chain alkanes and the 
alkB are often integral membrane bounded proteins, the cytochrome P450 
monooxygenases have received much more attentions due to their broad 
substrate spectra, regio- and enantiospecific manner as well as efficient 
recombinant enzyme expression and production, while engineering of MMOs 
seems almost impossible today. However, most of the cytochrome P450 
monooxygenases show terminal hydroxylation selectivity, and only a few of 
them demonstrate hydroxylation at non-activated subterminal position, and 
their regio- and stereoselectivity are unsatisfactory.91,105,106 Besides, most of the 
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cytochrome P450 monooxygenases show substrate preference of hydrophobic 
compounds, and only two cytochrome P450 monooxygenases were reported to 
be capable of catalysing ω-hydroxylation of primary alcohols with very low 
yield and selectivity.107 Moreover, most cytochrome P450 monooxygenases 
show unsatisfactory activity in the hydroxylation of non-natural substrates, such 
as fluoro-containing compounds.108,109 All of these drawbacks limit the further 




This thesis aims to explore the potential of creating a set of engineered P450pyr 
monooxygenases for highly active and efficient regio- and/or enantioselective 
biohydroxylation. More specifically, the thesis objectives are (Figure 1.3): 
 To create P450pyr variants for the highly regio- and enantioselective 
subterminal hydroxylation of alkanes through directed evolution. The n-octane-
P450pyr docking model was obtained and used to select key amino acids for 
iterative saturation mutagenesis (ISM) and screening. A novel, accurate, 
sensitive, and simple colorimetric high-throughput screening (HTS) assay was 
developed for the measurement of both the regioselectivity and 
enantioselectivity of a hydroxylation reaction. Six rounds of evolution were 
performed, and one P450pyr variant was created for the hydroxylation of n-
octane to give (S)-2-octanol with 98 % ee and > 99 % subterminal selectivity. 
The kinetic properties of this variant was also investigated. 
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 To create P450pyr variants for highly regioselective terminal 
hydroxylation of n-butanol to 1,4-butanediol through directed evolution. The n-
butanol was docked into the crystal structure of P450pyr, and key amino acids 
were selected for ISM. A surrogate substrate-based colorimetric HTS method 
was developed for the HTS. Two rounds of evolutions were conducted and the 
P450pyr biohydroxylation activity toward n-butanol was successfully created 
and further improved.   
 To discover P450pyr variants for the highly regioselective 
hydroxylation of fluoro- and other halo-substituted toluenes. All the available 
P450pyr variants were tested for the enzymatic hydroxylation of 4-
fluorotoluene. The P450pyr variant which showed the highest activity as well 
as regioselectivity was identified. The activity and regioselectivity of this 
P450pyr variant for the hydroxylation of other fluoro-, and halo-substituted 
toluenes as well as multiple fluoro-substituted toluenes were also investigated. 
 
 







•A brief introduction of the background, importance and objectives for
directed evolution of P450pyr monooxygenase for regio- and/or
enantioselective hydroxylations.
Chapter 2
•Literature review on enzyme, monooxygenase, P450 monooxygenase,
protein engineering, and high-throughput screening methods.
Chapter 3
•Topic1: directed evolution of P450pyr monooxygenase for highly
enantioselective subterminal hydroxylation of n-octane.
Chapter 4
•Topic2: directed evolution of P450pyr monooxygenase for highly
regioselective terminal hydroxylation of n-butanol to 1,4-butanediol.
Chapter 5
•Topic3: application of P450pyr monooxygenase variants for highly






 Chapter 2: Literature Overview 
2.1 Enzymes 
Enzymes are essential biological molecules in all living organisms since they 
are indispensable for cell metabolism, signal transduction, biosynthesis and 
detoxification.110,111 Enzymes are also impressive catalysts that can catalyse a 
wide range of complex chemical reactions with high selectivity. Based on the 
types of reactions they catalyse, enzymes could be classified into six major 
categories (Table 2.1). 112  
Table 2.1 .112 





Reactions Catalysed Examples 
EC 1 Oxidoreductases Catalyse oxidation and/or reduction 
Dehydrogenases, 
oxidases 
EC 2 Transferases 
Transfer of functional group from one 
molecule to another 
Kinases, 
transaminases 
EC 3 Hydrolases Hydrolysis of substrates Digestive enzymes 
EC 4 Lyases 
Addition or removal of functional 
group to a substrate 
Decarboxylases, 
aldolases 
EC 5 Isomerases 




EC 6 Ligases 





It was estimated that currently about 60% of biotransformations in chemical 
industry rely on the use of hydrolases, and about 20% reactions using 
oxidoreductases.113 With the development of green and sustainable chemical 
and pharmaceutical production, oxidoreductases have become increasingly 
popular and important due to its high reaction efficiency and low waste 
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generation.114  Oxidoreductases are a class of enzymes that catalyse the transfer 
of electrons from one molecule (electron donor) to another molecule (electron 
acceptor), resulting in reactions involving electron transfer, proton abstraction, 
hydrogen extraction, and hydride transfer or oxygen insertion.115 Although 
oxidation/reduction is one of the most useful reactions, it is still problematic by 
using traditional organic chemical catalysts, and therefore oxidoreductases have 
become promising alternatives for such challenge.116 There are mainly four sub-
classes of oxidoreductases, namely: reductases, oxidases, oxygenases and 
dehydrogenases (Figure 2.1).  
 
Figure 2.1 Assignment of monooxygenases to enzyme classes. Monooxygenases are associated 
with the grey coloured subdivisions.  
 
Whereas dehydrogenases catalyse a substrate by transferring one hydrogen to 
an acceptor; reductases catalyse the reductions of substrates; oxygenases 
irreversibly incorporate oxygen atoms into substrates; and oxidases catalyse the 
transfers of electrons between different substrates. Within these enzymes as 
mentioned, oxygenases are of particular interest as they could directly use 
molecular oxygen from air as a cheap, green and non-toxic oxidant. However, 
so far the industrial applications of oxygenases are still limited due to their poor 
15 
 
stability in non-native environments and unsatisfied activity and selectivity 
toward non-natural substrates. With the advancements in protein engineering, 
the catalytic properties of several oxygenases have been successfully improved 
and applied in industrial chemical synthesis.117 
 
2.2 Monooxygenases 
Monooxygenases belong to a subclass of oxygenases; they incorporate one 
hydroxyl group into substrate. During this reaction, two atoms of oxygen are 
reduced to one hydroxyl group and one water molecule by the concomitant 
oxidation of NAD(P)H.118 It is a very big and diverse group of enzymes that 
found in all living organisms as monooxygenases are critical for detoxification 
and clearance of xenobiotics which are excreted in urine after hydroxylation 
reactions.116 Furthermore, in organic synthesis, monooxygenases is the general 
solution for carbon functionalisation, especially for the regio- and 
enantioselective hydroxylation, which is still problematic for classic 
chemistry.119 Many monooxygenases, such as P450s (P450BM3, P450cam and 
P450pyr),120-122 methane monooxygenases (MMO),123,124 and membrane-bound 
alkane hydroxylase (alkB),125,126 have been discovered and extensively 
investigated to exploit their functions as biocatalysis, and some of them have 
already been engineered for different target reactions.127-129 
2.2.1 Methane Monooxygenase (MMO) 
Methane monooxygenase (MMO) belongs to the class of oxidoreductases 
which is capable of oxidising the C-H bond in methane and other small 
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alkanes.130 There are two forms of MMO, one is soluble methane 
monooxygenases (sMMO) which contains a Fe-O-Fe centre,131 and the other 
form is particulate methane monooxygenases (pMMO) whose active site 
utilises copper.132 These two well-known MMO were identified from 
Methylococcus capsulatus Bath 133-136 and Methylosinus trichosporium OB3b, 
respectively.137-140 Both of the two MMO could hydroxylate a series of alkanes 
to alcohols by using NADH as cofactor.141 However, their highest activity is 
only obtained with methane as the substrate, and their activity will significantly 
decrease when the substrate chain length increases.  
2.2.2 Alkane Hydroxylase (AlkB) 
Similar to MMO, alkane hydroxylases (AlkB) is a group of enzymes which are 
responsible for the hydroxylation of medium to long chain alkanes. It is an 
integral membrane-bound non-heme iron monooxygenase, usually consists of 
three components: AlkB, rubredoxin and rubredoxin reductase. For instance, 
GPo1 from Pseudomonas oleovorans is one of the most famous AlkB enzyme 
which catalyses a wide range of substrates from alkanes to fatty acids.125,126 
Although the substrate scope of AlkB is wide, the industrial application of this 
class of enzymes is still limited due to its complexity and poor solubility. As a 
membrane-bound enzyme, the solubility of AlkB in the aqueous medium is very 
low, which strongly limit its industrial applications. Furthermore, membrane-
bound enzymes are generally not suitable for protein engineering as it is difficult 




2.2.3 Cytochrome P450 Monooxygenase 
Cytochrome P450 monooxygenase (CYP or P450s) is one of the largest and 
oldest superfamily of heme-containing enzymes that utilises molecular oxygen 
and NAD(P)H to carry out the oxidative insertion of a single oxygen atom into 
X-H bonds (X: C, N or S) of an organic substrate with the concomitant reduction 
of the other oxygen atom to water.144,145 Interestingly, these enzymes are named 
not based on their functions but rather due to their characters: “cytochrome” 
represents a hemoprotein, “P” stands for pigment, and “450” reflects the typical 
absorption spectra of the reduced CO-bound CYP complex which occurs at 450 
nm.146 Remarkably, P450s have a wide substrate scope including alkanes, 
terpenes, alkaloids, fatty acids; and they also catalyse oxidation (hydroxylation, 
epoxidation, dealkylation, etc) often in a regio- and/or enantioselective manner 
under mild conditions.127,147,148 To date, 267 families with more than 7000 
P450s have been identified and sequenced. Many soluble bacterial P450s are 
overexpressed in heterologous hosts for synthesis, and some of them have 
already been characterised with 3D structures.149,150  
2.2.3.1 Cytochrome P450 Monooxygenase Classes  
Based on how electrons from NAD(P)H are delivered to the catalytic site, P450s 
could be mainly classified under four classes (Figure 2.2), although other 
subclasses are occurring as well: bacterial type, mitochondrial type, microsomal 
type and one special self-sufficient type.  
The bacterial type P450s is a three-component system with flavin adenine 
dinucleotide (FAD) containing a reductase, an iron-sulphur redoxin and the 
heme-containing P450 enzyme (Figure 2.2A). This type of P450s is involved in 
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the catabolism of compounds used as carbon source,151,152 and production of 
biologically active secondary metabolites such as antibiotics.84,153  
Similar to bacterial type, mitochondrial type P450s also contains three separate 
parts: a FAD-containing reductase, which transfers reduction equivalents from 
NAD(P)H; a ferredoxin, which in turn reduces the cytochrome P450 itself. 
However, in bacterial type P450s all three proteins are soluble (Figure 2.2A); 
while in mitochondrial type P450s only the ferredoxin is a soluble protein, 
whereas both the reductase and the cytochrome P450 are bounded to the inner 
of mitochondrial membrane (Figure 2.2B). In mammals, this type of P450s 
plays an essential role in the biosynthesis of the cholesterol-derived steroid 
hormones, vitamin D and bile acids.154 One example of mitochondrial P450s is 
CYP11B1, which responses for the formation of cortisol by the 11β-
hydroxylation of its precursor 11-deoxy-precursors.155-157  
The microsomal type P450s is the most common groups of P450s that located 
in the endoplasmic reticulum (ER) of mammals. This type of P450s contains 
two integral membrane proteins (Figure 2.2C): the P450 and the microsomal 
NADPH-P450 reductase containing FAD and FMN.158 The substrate range of 
this type of P450s is extremely diverse: including fatty acids, steroids, as well 
as exogenous compounds such as therapeutic drugs and environmental 
toxicants.159  
The self-sufficient type of P450s is an unusual species where the P450 itself is 
bound to its reductase component into a single polypeptide chain, and thus is 
catalytically self-sufficient (Figure 2.2D). The first and most famous member 
of this self-sufficient group of P450s is CYP102A1 (P450BM3), which was 
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discovered from soil bacterium Bacillus megaterium in 1980s.160 The self-
sufficient type of P450s (e.g. P450BM3 and P450Rhf) has been discovered in 
both prokaryotes and eukaryotes, and interestingly all of them show similar 
substrate scope, molecular weight, catalytic turnover, and many other enzymatic 
characters.161-164   
 
Figure 2.2 Schematic representation of the different cytochrome P450 systems. A: bacterial 
system, B: mitochondrial system. C: microsomal system, D: self-sufficient system (CPR 
fusion type). 
 
2.2.3.2 Hydroxylation Mechanism of Cytochrome P450 Monooxygenase  
Although the detail information of different P450s catalysed reactions is still 
growing, the hydroxylation mechanism has been well understood and could be 
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generally described in Figure 2.3.165-167 The catalytic cycle is considered to start 
with the binding of substrate to the active site (heme centre) of the P450s. Then 
an electron is transferred from NAD(P)H and ferric iron is reduced at the same 
time. Subsequently, a molecular oxygen binds to the ferrous iron group, and 
another electron is accepted to produce a negatively charged iron-peroxo 
intermediate. This intermediate is unstable and will quickly be protonated to 
create a highly reactive iron-hydro-peroxo complex, which also known as P450 
Compound 1 [Fe(V)=O]. This intermediate allows substrate attack to generate 
a hydroxylated product which would detach from the heme centre.168 Finally, a 
water molecule binds to the P450s heme centre, and the enzyme returns to the 
initial state for the next cycle of reaction. 
 
Figure 2.3 The catalytic cycle of cytochrome P450 
 
2.2.3.3 Cytochrome P450cam Monooxygenase 
P450cam is a typical bacterial type of P450s which consists of three separate 
parts: putidaredoxin, P450cam and iron-sulphur ferredoxin which transfer 
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electrons between putidaredoxin and P450cam.169 This enzyme was isolated 
from Pseudomonas putida and it converts camphor to 5-exo-hydroxycamphor 
natively, hence the name P450cam.170  
The substrate scope of wild-type P450cam, however, is quite narrow due to the 
existence of complementary interactions in P450cam activity site. Since the 
identification of P450cam crystal structure,171 protein engineering has been 
extensively used to increase the activity and selectivity of P450cam for the 
oxidation of non-natural substrates (Figure 2.4). Many novel mutated enzymes 
had been created that showed selective hydroxylation activity toward phenyl 
derivatives, while wild-type P450cam did not accept any of these compounds 
as substrate for hydroxylation.172 Other valuable mutants, which showed very 
high activity toward small and medium chain alkanes, were also generated via 
the replacement of certain key amino acid residues with bulky amino acid 
residues.173-176 
 
Figure 2.4 The substrate scope of P450cam and its variants.  
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2.2.3.4 Cytochrome P450BM3 Monooxygenase 
P450BM3(CYP102A1), a fully soluble fatty acid hydroxylase with a molecular 
weight of 119 kDa, is the most extensively examined and engineered P450s 
owing to the following unique properties.177 178 Firstly, high activity, the 
hydroxylation of fatty acid catalysed by P450BM3 is the most rapid P450-
catalysed hydroxylation reactions known thus far (kcat = 17,000 min-1).161 
Secondly, solubility, P450BM3 is not membrane-bound but is conveniently 
fused to its reductase, which makes the expressing better.127 Last but most 
importantly, P450BM3 tolerates mutations which allows extensive protein 
engineering studies to be carried out. To date, many interesting P450BM3 
mutants have been (and are still being) created which are capable of: accepting 
non-natural substrates (Figure 2.5); exhibiting very high activity with very high 
regio- and enantioselectivity toward target substrates.63,179-183 The natural 
substrate of P450BM3 is fatty acids containing 12-22 carbons, and the products 
are mixture of ω-1, ω-2 and ω-3 hydroxylated fatty acids.184 With directed 
evolution, a library of P450BM3 variants with measurable activity on various 
linear terpenes, cyclical monoterpenes, and cyclical sesquiterpenes were 
successfully created.185 Further work on P450BM3 evolution had expanded its 
substrate specificity from fatty acids to other non-natural substrates such as 
alkanes, aromatics and steroids.121,168  In addition, the stability of P450BM3 was 
also improved when six amino acids mutation were introduced in its active site. 
This new created thermos-stabilised P450BM3 could increase the half-life from 




Figure 2.5 The substrate scope of P450BM3 and its variants. 
 
2.2.3.5 Cytochrome P450pyr Monooxygenase 
The cytochrome P450pyr monooxygenase was isolated from Sphingomonas sp. 
HXN-200, which was discovered by Li et al. in 1999 for the regio- and 
stereoselective hydroxylation of N-benzyl pyrrolidine.187,188 This soluble 
P450pyr monooxygenase is a member of the cyp153 family and belongs to the 
class I of P450s which need an extra electron-delivering system (ferredoxin and 
ferredoxin reductase protein) (Figure 2.6). Besides, this family of P450s can 




Figure 2.6 Regio- and stereoselective hydroxylations with P450pyr monooxygenase system. 




The discovery of P450pyr is of great interest due to its high activity and 
excellent regio- and stereoselectivities on a variety of alicyclic substrates such 
as piperidines, azetidines, 2-pyrrolidinones and 2-piperidinones.189-191 Medium 
chain alkanes from pentane to nonane are also accepted as substrates, and most 
importantly, P450pyr catalyses the hydroxylation of these alkanes at terminal 
position exclusively. Besides, this P450pyr is also a good epoxide hydrolase 
which converts N-benzyloxycarbonyl-3,4-epoxy-pyrrolidine and cyclohexene 
oxide to their corresponding vicinal trans-diols in high ee and high yield.192 Its 
wide substrate range makes P450pyr an suitable target enzyme for directed 
evolution.  
While the substrate scope of P450pyr is diverse, it is confined to mostly 
medium-sized hydrophobic substrates (Figure 2.7). No activity towards smaller 
molecules, such as n-butane or hydrophilic molecules such as alcohols has been 
discovered. This phenomenon is not surprising as the primary role of P450s is 
detoxification by hydroxylation of hydrophobic molecules to more hydrophilic 
alcohols. Recently, several new P450pyr mutants were generated by directed 
evolution with improved S-enantioselectivity or R-enantioselectivity for the 
hydroxylation of N-benzyl pyrrolidine, enhanced regioselectivity for the 
hydroxylation of N-benzyl pyrrolidinone, and increased enantioselectivity for 
the hydroxylation of N-benzyl piperidinone, respectively.102,103 One engineered 
P450pyr variant was also found to catalyse the asymmetric epoxidation of para-
substituted styrenes, unconjugated 1,1-disubstituted alkenes and cyclic alkenes, 





Figure 2.7 The substrate scope of P450pyr and its variants. 
 
2.3 Protein Engineering 
Most of the natural enzymes are generally unsuitable as catalysts for industrial 
processes, which often occur at harsh and extreme conditions that will cause the 
enzymes to degrade and denature; furthermore, natural enzymes also have weak 
activity and selectivity toward non-natural substrates.193 Since 1990s, protein 
engineering has become one of the most  powerful and promising tools to adapt 
natural enzymes for industrial applications. Based on the use of recombinant 
DNA technology, protein engineering could create new enzymes with desirable 
properties, including: substrate specificity, improved kinetics, high stability, 
good solvent tolerance and substrate/product inhibition. In general, protein 
engineering can be accomplished through two experimental routes - rational 
design and directed evolution. 
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2.3.1 Protein Engineering by Rational Design 
The most classical approach in protein engineering is via rational design, which 
always relies on the information of the protein structure, knowledge about 
protein folding, dynamics as well as structure-function relationship.194 It utilises 
computational design to predict optimal mutations at specific target sites in the 
protein, followed by site-directed mutagenesis to confirm the prediction. It is an 
effective and less labour intensive approach, since only certain key amino acid 
residues have to be isolated and changed to other amino acids with different 
properties.195-197  
The catalytic performance of many enzymes have been successfully improved 
through rational design approach.198-200 For example, by using a computer 
model to illustrate key mutations in the active site and substrate access channel, 
Keasling et al developed of a four-point P450BM3 mutant, which increased the 
coupling efficiency for epoxidation of amorphadiene from 35% to 63% and the 
epoxidation rate from 8 to 30 per min.201 However, in many cases, the crystal 
structure and catalytic mechanism of the enzyme of interest is not available. 
Under this limited or absent information condition, protein engineering can still 
be accomplished through another approach: directed evolution.  
2.3.2 Protein Engineering by Directed Evolution 
Directed evolution is an alternative approach to bridge the gap between natural 
enzymes and desired enzymes. It involves a creation of genetic diversity, 
followed by screening and selection for mutants with the desired features.202 It 
is an iterative Darwinian optimisation process, where only the “fittest” variants 
are iteratively selected from a mutant library.25,203-205  
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Compared with millions years of natural evolution, directed evolution is 
certainly a fast approach that can generate desired enzymes from a greater 
number of parents within several months’ time. In contrast to rational design, 
directed evolution does not require the knowledge of protein structural nor the 
mechanism of catalysis, and can be carried out with just the knowledge about 
the enzyme’s genetic sequence.206 A general comparison of these two methods 
is summarised in Figure 2.8. 
 
Figure 2.8 A comparison of directed evolution and rational design processes. 
 
In the present day, directed evolution has become increasingly popular with the 
development of molecular biology technologies and high-throughput screening 
(HTS) techniques. Figure 2.9 summarises the three main mutant library 
generation methods: random mutagenesis, semi-rational design, and gene 
shuffling. Random mutagenesis could introduce mutations at any positions 
throughout the whole gene sequence, while semi-rational design only mutates 
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genes at specific position of interest. Moreover, gene shuffling could exchange 
the DNA fragments from different parental DNA sequences. As molecular 
biology technologies continue to improve, the boundary between rational design 
and directed evolution has become more and more indistinct. Researchers have 
combined both methods to generate many new enzymes with better catalytic 
properties.207,208 One of such techniques that combines rational design and 
directed evolution is iterative saturated mutagenesis(ISM). In this method, key 
amino acids are identified based on the protein structure and then exchanged 
with all other amino acids generating a smaller library size compared with gene 
shuffling or error-prone PCR. Besides, this method has been proven to be more 
efficient than gene shuffling for the directed evolution of β-Galactosidase.209 
 
Figure 2.9 Three main mutant library creation strategies: random mutagenesis; semi-rational 
and gene shuffling. 
 
2.3.2.1 Iterative Saturation Mutagenesis (ISM) 
In order to address the limitations of both rational design and directed evolution, 
in 2007 Reetz et al introduced a new and efficient “semi-rational” approach for 
the protein engineering, iterative saturation mutagenesis (ISM).205 Based on the 
available protein structure, iterative cycles of saturation mutagenesis are 
performed at rationally selected sites; this method could reduce the necessary 
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mutant library generation and the screening effort drastically. In general, there 
are five steps in the ISM process (Figure 2.10):  
1. Based on the enzyme structural data, identify the key amino acids that 
may be important for improving certain property;  
2. Perform individual site-saturation mutagenesis of all selected residues; 
3. Screen all the mutants with HTS and then identify the best hit; 
4. The best mutant is used as the template for another round of saturation 
mutagenesis at the remaining unmutated sites, and repeat steps 2-4 until 
no further improvement can be achieved. 
5. Analyse the relationship between mutated amino acids and created 
properties.  
 
Figure 2.10 General process (A) and mechanism (B&C) of ISM 
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Since it was reported, the catalytic performances of many enzymes have been 
successfully engineered through ISM method, such as: increased stability of 
lipase from Bacillus subtilis;24 broadened substrate scope of the old yellow 
enzyme homologue YqjM with improved enantioselectivity for bioreduction of 
substituted cyclopentenone and cyclohexenone derivatives.210 This ISM method 
has two unique advantages. First, it ensures all important amino acid 
substitutions at each critical site. Degenerated primers were designed at certain 
amino acid residues with the sequence of NNK and other 9-12 bases on the left 
and right (Figure 2.10C). The NNK sequence encodes for all 20 amino acids 
(32 possible codon substitutions). Second, it maximises the probability of 
obtaining cooperative effects of newly introduced mutations in a minimised 
mutant library size. This ISM process (Figure 2.11B) is significantly different 
from the common method of using multiple cycles of epPCR or gene shuffling. 
For the latter two methods, they address the whole enzyme sequence, which 
means that in each cycle all the amino acids are covered over and over again, 
though maybe only very few sites are really useful for certain properties. 
However, a clear limitation of this ISM approach will become obvious when 
attempting to engineer an enzyme of which no structural data (X-ray or 
homology model) is available. In such cases epPCR or DNA shuffling may be 
the method of choice. 
One specific form of the ISM is combinatorial active site saturation test 
(CASTing), which was originally developed with the purpose of expanding the 
range of substrate acceptance of an enzyme.211 Usually there are only three steps 
in the CASTing:  
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1. Based on the 3D structure of the enzyme, two or three amino acids, 
whose side chains reside next to the binding pocket, are identified.  
2. Each positions are randomised simultaneously with the creation of 
relatively small libraries of mutants. 
3. Screen all the mutants with HTS and identify the best hit.   
Compare to typical ISM, usually two or three amino acids (rather than only one) 
are simultaneously randomised in CASTing, and therefore this approach 
theoretically allows the possibility of cooperative effects.212 Currently this 
method is considered as a useful alternative to epPCR as the starting point of 
directed evolution studies. 
2.3.3 Screening and Selection 
There are two steps in protein engineering: introduction of genetic 
diversification to create the variation, and selection of variants with desirable 
properties. Normally the later step is more challenging as it usually calls for the 
screening of thousands of mutants, which is tedious and time consuming.213 
Therefore, many effective HTS and selection techniques have been developed 
to quickly “get a needle in a haystack.”  
One of the most commonly used methods is microplate based screening due to 
their flexibility and automation.214 Variants from the mutant library are 
inoculated and grown in a 96-well plate, where enzymes of interest are 
expressed and subjected to an HTS assay based on UV-absorption, colorimetric, 
luminescence, or fluorescence.215 Many standardised equipment are 
commercially available to quantitatively analyse each screened mutant in a 96-
well plate, and mutants with desired absorbance/fluorescence could be 
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identified and selected efficiently. Many other HTS and selection methods have 
also been reported, such as: agar plate growth-based and flow cytometry-based 
selection and screening, and whole-cell based compartmentalization screening 
approach.216 However, all these reported methods are highly dependent on the 
substrate/enzyme combination, and therefore understanding the advantages, 
disadvantages and limitations of each method at different conditions is crucial 
to choose the best HTS and selection approach.  
In addition, many HTS methods selection processes involve a balance between 
substrate selection, assay complexity, and detection limit. Sometimes a 
“surrogate” substrate has to be used in HTS, though the screening process 
becomes more convenient, this route might tailor the enzyme towards the 
“surrogate” substrate not the “target” substrate.217 In general, a well-designed 
HTS screening system is essential for successful protein engineering, which 
reduce experimental efforts and increase the chances to identity a mutant with 
desirable properties. 
2.3.3.1 Screening Methods to Determine the Enantioselectivity 
There are a few screening and selection methods reported for enzyme 
enantioselectivity determination.218-222 The most direct and traditional method 
to analyse an enzyme’s enantioselectivity is to determine the product ee by 
either chiral GC or HPLC. Though both methods could provide precise data, 
these two methods are still considered as “medium throughput”, since normally 
only about 200 samples could be measured per day per machine. Several 
indirect methods have been developed to quickly estimate the product ee in a 
more efficient way. For instance, product ee could also be determined by further 
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transformation of product enantiomers with enantioselective enzymes and then 
detected by UV spectroscopy or IR thermography.223,224  
Based on this idea, Li et al created an HTS method for the determination of 
alcohol ee by utilising two complementary alcohol dehydrogenases.225 Recently, 
NBT-PMS colorimetric assay was then introduced to make this concept more 
easily applicable in directed evolution, and a two-enzyme based colorimetric 
HTS assay was developed for the asymmetric biohydroxylation.226 By using this 
assay, the enantioselectivity of P450pyr for the biohydroxylation of N-benzyl-
3-pyrrolidine was inverted from ee of 43% (S) to 83% ee (R) with three rounds 
of evolutions (Figure 2.11). 226  
 
Figure 2.11 Principle of high-throughput screening for the screening of (S)- and (R)-1-benzyl-
3-pyrrolidinol. 226 
 
Recently, another interesting high-throughput MS screening method for 
enantioselectivity was reported.227 Different with enzyme-based assay 
described above, this method was adopted by using two enantiomers of 
isotopically labeled substrate for parallel enzymatic hydroxylations, coupled 
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with MS detection. The principle is shown in Figure 2.12, (S)-D- and (R)-D-
substrate are prepared and used for the hydroxylation, respectively. The O-D 
bond in the hydroxylation product changes quickly to O-H in the aqueous 
medium to give a mass of M, and other hydroxylation products still have a mass 
of M+1. The peak ratio of M and M+1 in MS can be easily determined and then 
used to calculate the product ee based on Equation (1) and (2). By using this 
method, the enantioselectivity of P450pyr for the biohydroxylation of N-benzyl-
3-pyrrolidine was improved from ee of 43% (S) to 98% (S) with 80% relative 
activity as compared to the wild-type P450pyr.103 
 
Figure 2.12 Principle of mass-spectrometry based high-throughput screening using deuterated 
substrates. 103 
 
2.3.3.2 Screening Methods to Determine the Regioselectivity 
The principle of some reported regioselective HTS method is very similar to the 
two-enzyme based enantioselective HTS assay. For instance, Lentz et al 
developed an HTS procedure that is capable of discriminating between terminal 
and other position carbon chains hydroxylation products.228 As shown in Figure 
2.13, the yeast alcohol dehydrogenase, which has an oxidation rate that is 10 
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times higher for primary alcohols than for secondary ones, was used and the 
process was monitored through NADH formation with a spectrophotometer.228 
 
Figure 2.13 Principle of high-throughput screening for the terminal selective hydroxylation of 
n-octane. 
 
Apart from these types of enzyme-based HTS methods, other chemical based 
direct regioselective colorimetric HTS assays were also reported. For example, 
the “surrogate” substrate hexyl methyl ether (HME) was used in the evolution 
of P450BM3 for the terminal alkane hydroxylation.229 As shown in Figure 2.14, 
terminal hydroxylation of HME would produce a formaldehyde, which turned 
purple colour in the presence of Purpald reagent. By using ISM and this 
screening method, a P450BM3 mutant with 52% terminal selectivity of octane 
was discovered.229 Based on the similar mechanism, some other “surrogate” 
substrates like: nitro-4-(octyloxy)benzene (NOB) and dimethylether (DME) 
were also used in the engineering of highly regioselective enzyme.230 
 
Figure 2.14 Screening for terminal alkane hydroxylation using hexyl methyl ether (HME). 
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2.3.4 Engineering P450s for New Substrate Specificity and Higher 
Catalytic Activity and Selectivity 
Over the past two decades, several P450 monooxygenases have been 
sucessfully engineered via directed evolution for the highly ative regio- and/or 
enantioselective hydroxylation of certain target substrates.  
By using a combination of directed evolution and site-directed mutagenesis, 
Frances H. Arnold and co-workers sucessfully engineered P450BM3 for the 
alkane hydroxylation. The wild-type P450BM3 shows a very poor chemo-, 
regio- and enantioselectivities in the oxidising of n-octane, the oxidation 
product is a mixture of 4-octanol, 3-octanol, 2-octanol, 4-octanone, and 3-
octanone, besides the activity is also much lower than for the hydroxylation of 
its natual substrate C12 to C18 fatty acids (Figure 2.15).148 By using a surrogate 
substrate-based colorimetric  HTS  assay, several variants with more than 5 
times improved activity were identified after two rounds of evolutions. After 
that, a NADPH consumption HTS assay with n-octane as the substrate was 
combined with this colorimetric HTS assay, and two active mutants were 
generated after several rounds of error-prone PCR, DNA shuffing and site-
directed mutagenesis. One variant hydroxylates n-octane at the subtreminal 2-
position to produce (S)-2-octanol (40% ee). Another variant, also hydroxylates 
n-octane at the 2-position but forms (R)-2-alcohols (40-55% ee, Figure 2.15).106 
Besides, these two biocatalysts are highly active, and the maximum  turnover 




Figure 2.15 Regio- and enantio-selective hydroxylation of n-octane with P450BM3 and 
engineered P450 BM3. 
 
Recently, this P450BM3 has also been successfully engineered by Manfred T. 
Reetz and co-workers through laboratory evolution for the regio- and 
stereoselective hydroxylation of steroids. In their inital experiment, the 
P450BM3(F87A) was discovered to be active for the hydroxylation of 
testosterone, but resulting in a 1:1 mixture of 2β- and 15β-alcohols. To 
maximise the probability of cooperative effects within a given site and between 
sites, selected residues were grouped first and ISM was applied to generate 
P450BM3 variants. After screening 8,700 mutants with HPLC, variants with 
96–97 % selectivity for either 2β- and 15β-isomers were obtained, both of them 
showed complete diastereoselectivity (Figure 2.16).231 Moreover, these two 
mutants also showed increased product formation and NADPH consumption. 
 




To investigate the activity and selectivity of P450BM3 and its variants for the 
hydroxylation of aromatic compounds, Ulrich Schwaneberg and co-workers 
generated a designed P450BM3 library by site-directed mutagenesis. Methyl 2-
methoxy-3-methylbenzoate was selected as a model substrate and NADPH 
consumption assay was used to discover potential variant. One mutant, 
P450BM3(F87A/L188C) showed 535-fold improved catalytic activity towards 
methyl 2-methoxy-3-methylbenzoate compared to that of wild-type 
P450BM3.182Besides, this variant was also found to be able to selectively 
hydroxylate several carbonyl- or carboxyl-substitute toluene derivatives. In 
addition, this variant also showed some activity toward 3-fluorotoluene (but did 
not show any activity toward chloro- and bromotoluenes).  
 
Figure 2.17 Benzylic hydroxylation of 2-methoxy-3-methylbenzoate with wild-type P450BM3 
and engineered P450BM3.   
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 Chapter 3: Engineering of P450pyr Hydroxylase for the 
Highly Regio- and Enantioselective Subterminal 
Hydroxylation of Alkanes 
3.1 Introduction  
Regio- and enantioselective hydroxylation at a non-activated carbon atoms is a 
very useful reaction for the functionisation of alkanes, an abundant and cheap 
feedstock for chemical synthesis, and produce enantiopure alcohols that are 
useful and valuable synthons and pharmaceutical intermediates.119,189,232-234 
Despite of some progress with transition metal catalysts,235-237 this type of 
reaction still remains as a significant challenge in classic chemistry. On the other 
hand, nature has found a general solution for this reaction via monooxygenase 
using molecular oxygen as the non-toxic oxidant.238,239  Many monooxygenases 
such as the soluble cytochrome P450 monooxygenases (P450cam, P450BM-3, 
P450pyr),120,240,241 the soluble methane monooxygenases (sMMO),124,242,243 and 
the membrane-bound alkane hydroxylase (alkB)125,244 are known for this type 
of transformation. However, most monooxygenases such as MMO, alkB, and 
P450pyr only showed terminal hydroxylation selectivity,188,242,245,246 while 
P450BM-3 and P450cyp102A3 showed -1, -2 and -3 selectivity but the 
regio- and enantioselectivity are very poor.148,247  
Recently, directed evolution has become a useful tool to create new enzymes 
with improved catalytic performance.248-254 Using this approach, many 
monooxygenases have been engineered with new substrate specificity183,255-258 
and several with enhanced regio- and/or stereoselectivity179,229,247,259 for the 
40 
 
target hydroxylations. For instance, P450BM-3 mutants were engineered with 
excellent regio- and diastereoselectivity for the hydroxylation of testosterone 260 
and Artemisinin,261 respectively. Nevertheless, it is a challenge to develop an 
enzyme for non-terminal hydroxylation of alkane with excellent regio- and 
enantioselectivity: engineered sMMO and alkB mutants demonstrated some 
subterminal selectivity;125,262 engineered P450BM-3 mutants gave enhanced 
subterminal selectivity, with 89% regioselectivity and 65% enantioselectivity 
as the best results for the subterminal hydroxylation of n-octane;63,106,263 and 
engineered P450cam mutants showed subterminal hydroxylation of n-butane.264 
Nevertheless, there is no enzyme catalysing non-terminal hydroxylation of 
alkane with excellent regio- and enantioselectivity. 
We are interested in developing a set of new enzymes that are capable of 
subterminal hydroxylations with good regio- and enantioselectivities. We 
previously discovered a soluble P450pyr monooxygenase from Sphingomonas 
sp. HXN-200 as a powerful and best biocatalyst known thus far for terminal 
hydroxylation of N-substituted pyrrolidines, piperidines, azetidines, 2-
pyrrolidinones, and 2-piperidinones with high activity, high yield, excellent 
regioselectivity, and good to excellent enantioselectivity. 187,265-269 Recently, we 
succeeded in engineering P450pyr monooxygenase by directed evolution to 
create P450pyr mutants for the hydroxylations of N-benzylpyrrolidine with 
higher and inverted enantioselectivity.102,103  Our P450pyr is much better than 
P450BM-3 regarding the regio- and enantioselectivity in hydroxylations and 
shows different substrate specificity. Herein we wanted to engineer this 
P450pyr by directed evolution to create new P450pyr mutants for regio- and 
enantioselective subterminal hydroxylation. In this project, monooxygenase-
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catalysed subterminal hydroxylation of n-octane was selected as the target 
reaction. 
In order to achieve the aim of this project, we first developed a suitable 
colorimetric high-throughput screening (HTS) assay. We previously developed 
a HTS method for the determination of the ee of a chiral alcohol by the use of 
two enantioselective alcohol dehydrogenases. This method was further 
extending to determine both regio- and enantioselectivity at same time by using 
three regio- and enantioselective alcohol dehydrogenases. After set up the HTS 
method, protein engineering started with the identification of key amino acid 
residues that could influence the regio- and enantioselectivity. Based on n-
octane-P450pyr docking structure model, all residues within 6Å of the bound 
substrate were identified and subjected to ISM. The P450pyr was mutated at all 
the selected amino acid positions by using primers with mixed bases for the 
appropriate codon. The mutant genes were expressed in E. coli co-expressing 
Fdx and fdR. Biohydroxylations of n-octane with these colonies were examined 
based on the new developed HTS assay. Mutants with a higher subterminal 
selectivity and higher enantioselectivity were then selected as template for the 
next round of evolution.  Besides, the roles of the mutated residues on changing 
the regioselectivity and improving enantioselectivity were investigated based 
on the experimental results and simulation modelling, which could give insight 
into the understanding of the relationships between selectivity and structure of 




3.2 Experimental Section 
3.2.1 Strains, Media, and Materials 
T4 DNA quick ligase kit and deoxynucleotide (dNTP) Solution Mix were 
purchased from New England Biolabs (NEB). iProof DNA Polymerase was 
bought from Bio-Rad. DNA loading dye and DNA ladders were purchased from 
Thermo Scientific. Oligonucleotides were synthesised by AIT biotech, 
Singapore. LB Broth, bacto agar, tryptone, and yeast extract were purchased 
from Biomed Diagnostics. Antibiotics ampicillin and kanamycin, as well as 
YAD (Alcohol Dehydrogenase from Saccharomyces cerevisiae, lyophilized 
powder, ≥300 units/mg protein, Protein, ≥90%) were from Sigma-Aldrich.   
 
Table 3.1 Strains and plasmids used in this study 
Strain or plasmid Characteristic Reference 
E. coli DH5α Cloning strain Invitrogen 
E. coli BL21(DE3) Expressing strain Novagen 
pETDuet1       Expressing vector Novagen 
pRSFDuet1       Expressing vector Novagen 
pET28a   Expressing vector Novagen 
 
Following chemicals were purchased from Sigma-Aldrich and used without 
further purification: n-octane (≥ 99%), 1-octanol (≥ 99%), (S)-2-octanol (98% 
ee) and (R)-2-octanol (98% ee), nitro blue tetrazolium (NBT) (≥ 98%), 
phenazine methosulfate (PMS) (≥ 90%), Isopropyl β-D-thiogalactopyranoside 
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(ITPG) (≥ 99%), D-Glucose (≥ 99.5%), and NAD+ (≥ 96.5%). Other required 
salts and reagents were purchased from Fisher Scientific or Sigma-Aldrich.  
3.2.2 Generation of Mutant Library  
The mutant library at selected sites was generated using PCR with primers 
containing NNK codons covering all 20 possible amino acids. Each PCR 
reaction tube contained 2 μL each of forward and reverse degenerate primer of 
a particular target site, 10 μL iProof HF Buffer, 2 μL dNTP Solution Mix, 0.8 
μL MgCl2 solution, 0.1 μL (10 ng) template plasmid pRSFDuet-P450pyr, 0.5 
μL iProof DNA Polymerase, and 36.6 μL ultra-pure H2O. PCR amplification 
was carried out on MJ Research Thermal Cycler using the following thermal 
cycling protocol: 98 °C 3 min, (98 °C 10 s, 58 °C 30 s, 72 °C 4 min) × 30 cycles, 
72 °C 10 min.   
 
Table 3.2 Primers for site-directed mutagenesis and their melting temperatures 
Site Primers Tm* 
A77 
A77-F: CTC GTC CGA TNN KGG ATA TGG CG  




I82-F: GGA TAT GGC GGC NNK ATA ATC GAT GAC 




I83-F: GGC GGC ATC NNK ATC GAT GAC G  




I88-F: CGA TGA CGG CNN KCA AAA AGG  




Q89-F: GAC GGC ATT NNK AAA GGT GGC G  




L98-F: GCG GAC TGG ATN NKC CCA ATT TC  






P99-F: GGA CTG GAT CTT NNK AAT TTC ATC GCG  





N100-F: GGA TCT TCC CNN KTT CAT CGC  




I102-F: CCC AAT TTC NNK GCG ATG GAT C 




A103-F: CCA ATT TCA TCN NKA TGG ATC GGC C  




S182-F: CTT ACC CGC NNK TCG GAT GTG AC  




D183-F: GCT GGT CGN NKG TGA CAA CC  




T185-F: GGA TGT GNN KAC CGC AGC  




T186-F: GAT GTG ACA NNK GCA GCA CC     




L251-F: GTA CTT NNK CTG ATC GTT GGC G  




V254-F: CCT GAT CNN KGG CGG GAA C  




G255-F: CCT GAT CGT TNN KGG GAA CG  




D258-F: CGG GAA CNN KAC CAC ACG  




T259-F: CGG GAA CGA TNN KAC ACG C  




L302-F: GCA AAC ACC GNN KGC TCA TAT GC  




M305-F: CTT GCT CAT NNK CGC CGC ACG  




F403-F: CGT TCA AAT NNK GTG CGC GG  
F403-R: CCG CGC ACM NNA TTT GAA CG 
49.7 
49.7 




PCR products were subjected to DNA gel electrophoresis and the location of 
DNA in gel was detected using gel imaging system. The band containing the 
product was excised from the gel, purified using QIAquick Gel Extraction Kit 
(Qiagen), and the purified DNA was digested with methylated restrictive 
enzyme Dpn I at 37°C overnight. Finally, the mutant library creation was 
completed by transferring the digested DNA into E. coli BL21(DE3) competent 
cells containing the pETDuet-Fdx-FdR vector.  
3.2.3 General Procedure for Surrogate Substrate-based 
Colorimetric HTS Assay 
Mutants were inoculated and grown at 37 oC in 96-deep well plate with 600 μL 
TB medium per well. The expressing cultures were inoculated by transferring 
100 μL overnight culture into 900 μL expressing medium containing 50 μg/mL 
kanamycin, 100 μg/mL ampicillin, 500 μM IPTG, and 500 μM ALA. After 
expressing at 22 °C for 8 h, the cells were harvested by centrifugation at 3220 
g and 4 °C for 15min. The cell pellets were resuspended in potassium phosphate 
buffer (100 mM, pH 8.0) containing 5 mM surrogate substrate 4-nitrophenetole 
and 2 % (w/v) glucose.  
Biotransformation was performed for 4 hours at 30 °C and 800 rpm. The 96-
deep well plates were covered with gas-permeable seals during the whole cell 
growth and biotransformation process. The reaction was stopped by 
centrifugation at 3220 g for 15 min at room temperature. 100 μL of the 
supernatant from each well was transferred to a new 96-well plate and the 
absorbance at 410 nm was measured using Tecan Infinite M200 Microplate 




















Figure 3.1 The principle and procedure of surrogate substrate-based colorimetric HTS assay. 
(a) The principle: Biohydroxylation of 4-nitrophenetole at subterminal position generated an 
unstable hemi-acetal intermediate that decomposed to 4-nitropheol. The formation of 4-
nitrophenol can be determined by using a microplate reader based on UV absorption at 410 nm. 
(b) The procedure of the surrogate-substrate based colorimetric HTS assay.  
 
3.2.4 Genetic Engineering of E. coli Expressing CpSADH and E. coli 
Expressing PfODH 
The CpSADH and PfODH were cloned into pET28a plasmid (Figure 3.2). To 
construct these two plasmids, four primers were designed as listed in Table 3.3, 
both of the CpSADH and PfODH genes were amplified by PCR using MJ 
Research PTC-200 thermal cycler with the following program: 95 °C 5 min, 
(95 °C 30 s, 55 °C 30 s, 72 °C 1min) × 30 cycles, 72 °C 10 min.   
The PCR amplified CpSADH and PfODH fragments as well as expressing 
vector pET28a were then digested with their respective enzymes. The digestion 
products were purified again over 1% agarose gel in Tris-acetate-EDTA buffer. 
The ligation was conducted using T4 quick ligase kit. The ligation solution was 
then transformed into chemical competent E. coli DH5α cells, which were then 
plated on LB agar plates with appropriate antibiotics (50 μg/mL kanamycin and 
100 μg/mL ampicilin). The constructed plasmids were confirmed by DNA 
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sequencing. Finally, the purified plasmids were transformed into chemical 
competent E. coli BL21(DE3) cells and plated on LB agar plates containing the 
appropriate antibiotics.   
 
Table 3.3 Construction of pET28a-CpSADH and pET28a-PfODH plasmids. 
Gene to be 
amplified 




CpSADH-F (NdeI): GGGCA TATGT CAATC CCGTC CAGCC 




PfODH-F (NdeI): GGGCA TATGA GCTAC AACTT CCATA ATA 




Figure 3.2 pET28a-PfODH and pET28a-CpSADH expression vector 
 
3.2.5 Expressing and Purification of CpSADH and PfODH 
E. coli BL21(DE3) pET28a-CpSADH and E. coli BL21(DE3) pET28a-PfODH 
were cultured in LB medium containing 50 μg/mL kanamycin at 37 oC, 
respectively. At OD600 of 0.6-0.8, IPTG was added to a final concentration of 
500 μM and the temperature was reduced to 30 oC to induce the expression of 
his-tagged CpSADH and PfODH. After 12 h of expression, the cells were 
harvested by centrifugation at 3220 g and 4 oC for 15 min. The cell pellet was 
then re-suspended in binding buffer (50mM potassium phosphate buffer, 0.3 M 
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NaCl, 10 mM imidazole, pH 8.0) at OD600 of 30. Cells were broken by passing 
through cell disruptor at 21 psi for 2 times, followed by centrifugation (20376 
g, 4 oC, and 60 min). The his-tagged PfODH was expressed, harvested and 
broken under same condition.  
The his-tagged CpSADH and PfODH were purified by using ÄKTA purifier 
(GE Healthcare) system at 4 oC with UV at 280 nm to monitor protein 
concentration. The cell free extracts were loaded onto a Ni-NTA column, and 
non-his-tagged proteins were washed out by using 50 mM potassium phosphate 
buffer (pH 8.0) containing 0.3 M NaCl and 50 mM imidazole. The his-tagged 
protein was eluted by using 50 mM potassium phosphate buffer (pH 8.0) 
containing 0.3M NaCl and 500 mM imidazole. The fractions containing his-
tagged protein (CpADH or PfODH) were concentrated using Millipore Amicon 
Ultra-4 centrifugal filter device (10 kDa) at 3220 g and 4°C, washed three times 
with 50 mM potassium phosphate buffer (pH 8.0).  
3.2.6 Colorimetric HTS Assay Validation for the Determination of 
Regio- and Enantioselectivity in the Hydroxylation of n-octane  
The developed HTS assay was used to determine the terminal alcohol and the 
ee of subterminal alcohol by using samples containing different amount of (S)-
2-octanol, (R)-2-octanol and 1-octanol. In the first group of experiments, 81 
samples containing 1-octanol, (S)-2-octanol, and (R)-2-octanol at different ratio 
with the total concentration of 1.0 mM were used.  In the second group, 15 
samples with different total concentration and ratio (1-octanol was at 0.05 mM, 
0.5 mM, or 5 mM, and (S)- and (R)-2-octanol was at totally 0.5 mM but with 
different ratio) were examined. All samples were put in three microtiter plates, 
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and  reacted with YAD, CpSADH, and PfODH separately, in the presence of 2 
mg/mL NBT, 0.1 mg/mL PMS, and 1.0 mM NAD+. UV absorption at 580nm 
was recorded using a microtiter plate reader.  
3.2.7 General Procedure for Using the Colorimetric HTS assay in 
the Evolution of P450pyr Hydroxylase 
Mutants were grown and expressed under the same condition as given in section 
3.2.3. After harvesting, cells were re-suspended in potassium phosphate buffer 
(100 mM, pH 8.0) containing 5 mM n-octane, 2 % (w/v) glucose, and 2 (v/v) % 
DMSO. Biotransformation was performed in 96-deep well plate at 30 oC and 
800 rpm for 4 h.  
After reaction, the deep well plates were centrifuged, and 80 μL aqueous 
biotransformation mixtures were added into three 96-well plates, respectively. 
10 μL NBT-PMS solution (containing 2 mg/mL NBT, 0.1 mg/mL PMS and 1.0 
mM NAD+, final concentration) and 10 μL YAD, CpSADH or PfODH solution 
(0.5 U/mL) were added to each well of the microtiter plates, respectively. After 
incubation in darkness for 1 h at room temperature, OD580 was measured by 
using a microtiter plate reader. Mutants with improved subterminal selectivity 
and enantioselectivity were identified by comparing the two ratios of the 
corresponding absorbencies on three plates with the ratios for the parent enzyme 




Figure 3.3 The process of the new developed regio- and enantioselective colorimetric based 
colorimetric HTS assay. 
 
3.2.8 Whole-cell Biotransformation in Shaking Flask  
Positive mutants were selected and re-cultured on LB agar plate containing 50 
μg/mL kanamycin and 100 μg/mL ampicillin for overnight at 37 °C. The 
colonies were picked and inoculated in 3 mL LB medium and then shaken at 
250 rpm and 37 °C for 4 hours. The cells were then transferred in a 125 mL 
flask containing 25 mL TB medium with appropriate antibiotics. The culture 
was shaken at 250 rpm and 37 °C until the OD600 research 0.8. The cells were 
then induced for protein expression under 500 μM IPTG and 500 μM δ-ALA 
and the culture was shaken for additional 6 h at 250 rpm and 22 °C.  
Cell pellets were obtained by centrifugation at 3220 g for 15 min at 4 °C, washed 
with 30 mL distilled water, and centrifuged again at 3220 g for 15 min. The 
cells were re-suspended to 8 g cdw L-1 in 10 mL 100 mM potassium phosphate 
buffer (pH 8.0) containing 5 mM n-octane, 2% (w/v) glucose, and 2 % (v/v) 
DMSO. The biotransformation was performed in the shaking flask at 250 rpm 
and 30 °C for 4 h.  
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3.2.9 Analytic Method 
The activity and subterminal selectivity of the positive mutants for the 
hydroxylation of n-octane were determined by using Agilent 7890A gas 
chromatograph with HP-5 column (30 m × 0.32 mm × 0.25 mm). Temperature 
program: 80 oC for 1 min, then to 180 oC at 20 oC min-1, and finally to 230 oC 
at 50 oC min-1 for 1 min. Retention times: 3.87 min for 1-octanol and 3.32 min 
for 2-octanol. 
The ee value of 2-octanol was determined by using Agilent 7890A gas 
chromatograph with Macherey-Nagel Hydrodex-β-TBDAc column chiral 
column (25 m × 0.25 mm) at 70 oC. Retention times: 73.3 min for (R)-2-octanol 
and 74.8 min for (S)-2-octanol.  
The activity and subterminal selectivity of positive mutants for the 
hydroxylation of propylbenzene were determined by using Agilent 7890A gas 
chromatograph with HP-5 column (30 m × 0.32 mm × 0.25 mm). Temperature 
program: initial temperature 100 oC, then to 280 oC at 20 oC min-1, and finally 
hold at 280 oC for 2 min. Retention times: 3.29 min for 1-phenyl-2-propanol 
and 3.85 min for 3-phenyl-1-propanol. 
The ee value of 1-phenyl-2-propanol was determined by using Agilent 7890A 
gas chromatograph with Macherey-Nagel Hydrodex-β-TBDAc column chiral 
column (25 m × 0.25 mm) at 100 oC. Retention times: 40.1 min for (S)-1-phenyl-
2-propanol and 42.6 min for (R)-1-phenyl-2-propanol.   
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3.3 Results and Discussion 
3.3.1 Identification of Suitable Residues of P450pyr for ISM 
To identify the suitable residues for iterative saturation mutagenesis (ISM), n-
octane was docked onto the 3D structure of P450pyr (PDB ID 3RWL, Figure. 
3.4).103 The P450 enzyme was set to the ferry-oxo intermediate known as Cpd I 
state to mimic the actual binding geometry. The active pose of the substrate was 
concluded from the reported catalytic geometry.  
 
Figure 3.4 Spatial overview of the target sites for ISM based on the active docking pose of n-
octane (grey stick) in P450pyr hydroxylase. The heme was represented as ferryl-oxo complex 
known as CpdI state. 22 amino acid residues from seven major geometric areas were chosen for 
the mutagenesis. 
 
Based on the docking results, 14 residues located within 6 Å of the substrate 
molecule were selected and grouped in 4 parts, west (Ile82, Ile83, Ile102 and 
Ala103), north (Asn100, Thr186, Leu251, Val254 and Gly255), east (Asp258 
and Thr259) and south (Leu302, Met305 and Phe403). Three north-top residues 
(Ser182, Asp183 and Thr185) were also chosen due to their abrupt position in 
the substrate-accessing channel. In the previous study, a pocket reshaping was 
observed with the inward movement of the ‘big loop’ (Ser74-Asp105).This was 
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due to the increased rigidity contributed by the mutations that resulted in the big 
improvement in the enantioselectivity. As such, two groups of residues within 
12 Å from the docked n-octane, west big-loop (A77, I88 and Q89) and north 
big-loop (L98 and P99), were appended to the above-mentioned target sites. 
3.3.2 Creation of P450pyr Mutant Library for Directed Evolution  
For saturation mutagenesis at each targeted amino acid site, random mutations 
at the desired position of the P450pyr gene were generated by PCR using NNK 
degenerated codon. PCR products were then transformed into E. coli BL21(DE3) 
containing ferredoxin and ferredoxin reductase genes to create P450pyr mutant 
library. Figure 3.5 showed a typical result of DNA gel electrophoresis seen 
under a gel imaging system. The weak bands in the centre showed some 
presence of primer dimers, but the amplified DNA fragments were sufficient to 
create a mutant library. 
 
Figure 3.5 Mutant library generation with saturation mutagenesis. Imaging of gel 




3.3.3 P450pyr Mutant Library Quality Control  
In order to check the coverage and quality of the created mutant library, 12 
clones were randomly selected from site I82 mutant library. The cells were 
grown in culture tube with 5 mL LB medium at 37 °C for 8 h. The cell pellet 
was collected by centrifugation (2 min, 20376 g) and the plasmid was extract 
using Miniprep Kit (Qiagen). All the purified plasmid samples were sequenced 
by AITBiotech. As shown in Figure 3.6, there were 10 different types of amino 
acids within 12 randomly selected mutants. This confirms that the quality of the 
mutant library.  
 
Figure 3.6 The quality of mutant library I82 created with NNK degeneracy. The original amino 
acid was given on the top of the circle. Ten different created amino acids were represented with 
different colours. 
 
3.3.4 Development of Surrogate Substrate-based Colorimetric HTS 
Assay 
The first HTS assay for the subterminal hydroxylation screening was developed 
based on the mechanism described in Figure 3.1. This method allows screening 
of hundreds of mutants simultaneously within a very short time, which enable 
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one to analyse a mutant library within a reasonably time span. During reaction, 
P450pyr catalyses the subterminal hydroxylation of the surrogate substrate, 4-
nitrophenetole, into an unstable hemi-acetal intermediate, which in turn 
decomposes to a yellow compound, 4-nitrophenol, which could be monitored 
by taking absorbance reading at OD410. Improved mutants can be easily 
identified by comparing the absorbance value to that of the parent mutant. In 
order to find a suitable substrate concentration for the colorimetric HTS, 
samples containing different concentrations of both substrate and product were 
prepared and their absorbance at 410nm were detected. As shown in Table 3.4, 
the product absorbance at 410 nm was highly depending on solute concentration 
while the substrate was almost colourless at low concentration. The 100 μM was 
found to be the best substrate concentration for the colorimetric HTS assay. 
 
Table 3.4 The absorbance spectra for different concentrations of 4-nitrophenetole and 4-
nitrophenol were measured at 410 nm. 
 
410nM Blank 10μM 100μM 1mM 10mM 
4-nitrophenetole 
(Substrate) 
Sample1 0.043 0.044 0.045 0.053 0.078 
Sample2 0.044 0.043 0.045 0.052 0.078 
4-nitrophenol     
(Product) 
Sample1 0.044 0.750 3.626 3.692 3.892 
Sample2 0.043 0.761 3.662 3.685 3.894 
 
 
3.3.5 Directed Evolution with Surrogate Substrate-based 
Colorimetric HTS Assay 
The mutants’ subterminal hydroxylation activities were correlated to the 
amount of yellow 4-nitrophenolate produced, hence potential mutants could be 
identified by comparing the ratio of absorbance compared to wild-type P450pyr. 
A typical 96-well plate is shown below in Figure 3.7. Potential mutants with 
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subterminal hydroxylation activity could produce yellow even visible to the 
naked eye. In the first round of ISM, using wild-type P450pyr as a template, we 
screened 188 mutants per site, which translates into a total of 4136 mutants (22 
sites) screened. Finally, 6 potential mutants were identified from the first round 
of screening.  
 
Figure 3.7 A 96-well plate containing a mutant library for colorimetric HTS. Mutants with 
subterminal hydroxylation activity produce yellow 4-nitrophenolate visible to naked eye. 
 
All of the identified potential mutants were respectively inoculated to undergo 
further experiment to confirm their activity and regioselectivity of target 
substrate, n-octane. Within these six mutants, one mutant N100S displayed the 
best subterminal selectivity (5%) and activity. It was very interesting that only 
one amino acid changed at position 100 (replacing asparagine with serine) could 
create a subterminal hydroxylation selectivity.  
To further improve the subterminal regioselectivity and activity, a second round 
of evolution was applied by using N100S mutant as template. In this round, all 
left 21 sites were subjected to the ISM, and finally 20 potential mutants were 
selected after screening a 3948-mutant library. Mutant N100S/F403I was found 
to give the highest subterminal regioselectivity (33%) with significantly 
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improved relative activity (from 49 % to 110 %). This mutant was then used as 
template for the third round evolution, a triple mutant, N100S/F403I/T186I, was 
found to be the best mutant in this round, which gave 40% regioselectivity but 
the activity decreased to 44 % of the activity of wild-type P450pyr for terminal 
hydroxylation. 
3.3.6 Principle of Regio- and Enantioselective Colorimetric HTS 
Assay 
Limited improvement in past three rounds of mutagenesis suggests potential 
issues with the surrogate substrate based HTS method. Firstly, the surrogate 
substrate is structurally dissimilar to the target substrate, and therefore the 
activity and selectivity on the surrogate substrate is not equivalent to the activity 
and selectivity on the target substrate. We might have missed many mutants that 
have high subterminal regioselectivity toward n-octane but low or no activity of 
4-nitrophenetole. Secondly, this project requires the enzyme to have high regio- 
and enantioselectivity. While the current surrogate substrate-based colorimetric 
HTS assay does provide some regioselectivity information, it offers no 
information on enantioselectivity. Lastly, the absorbance measured in this assay 
is the product of activity and regioselectivity. In other words, a mutant with 
higher activity but lower regioselectivity can give a higher absorbance than 
another mutant with lower activity but higher regioselectivity. In order to solve 
all these limitations, a novel real substrate-based regio- and enantioselective 
colorimetric HTS assay was needed. 
The development of a real-substrate based regio- and enantioselective 
colorimetric HTS method was not an easy task. Most of the existing HTS 
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methods found in literature were mainly focused on improving the enzyme 
enantioselectivity in the kinetic resolution. Previously several novel, accurate, 
sensitive and simple HTS methods were established in our lab, and recently an 
enantioselective colorimetric HTS was developed based on two enantioselective 
alcohol dehydrogenases. Based on all these achievements, we decided to 
develop a novel colorimetric HTS assay to determine both regio- and 
enantioselectivity at the same time for the subterminal hydroxylation of n-
octane. 
Figure 3.8 illustrated the principle of the regio- and enantioselective HTS assay. 
Three NAD+-dependent alcohol dehydrogenases, that are highly specific for the 
oxidation of 1-octanol, (S)-2-octanol, and (R)-2-octanol, respectively, were used 
to separately oxidize the product mixture from a P450pyr variant-catalysed 
hydroxylation of n-octane in three parallel experiments. As shown in Figure 3.8, 
in the presence of NAD+, NBT, and PMS, the concentrations of 1-octanol, (S)-
2-octanol, and (R)-2-octanol can be obtained based on the UV absorption of 
Formazan at 580 nm. The subterminal selectivity and the enantioselectivity can 
be calculated by using equation (1) and (2), respectively. To prove the concept, 
a number of alcohol dehydrogenases were screened, and CpSADH from 
Candida parapsilosis,270 PfODH from Pichia finlandica,271 and YAD from 
Saccharomyces cerevisiae 228 were found to be highly specific for the oxidation 





Figure 3.8 Principle of the colorimetric HTS assay to measure both subterminal selectivity and 
enantioselectivity of P450pyr variant for the hydroxylation of n-octane. The concentrations of 
the possible hydroxylation products 1-octanol, (S)-2-octanol, and (R)-2-octanol are determined 
based on UV absorption of Formazan at 580 nm in the oxidation of the biohydroxylation mixture 
with highly selective alcohol dehydrogenase YAD, CpADH, and PfODH, respectively. The 
selectivities of the P450pyr variant are calculated using Eq (1) and (2). 
 
3.3.7 Genetic Engineering, Expressing and Purification of CpSADH 
and PfODH 
The CpSADH and PfODH genes were synthesised and codon optimised by 
Genscript Corp. (Piscataway, NJ). The sequences of the codon optimised 
CpSADH and PfODH are listed in Figure 3.9 and Figure 3.10, respectively. 
Both CpSADH and PfODH genes were cloned into the NdeI site and XhoI site 
of pET28a vector, respectively. Since both the CpSADH and PfODH genes had 
been codon optimised, after transformation of these two constructed plasmids 
into E. coli BL21(DE3) respectively, both CpSADH and PfODH genes were 




Figure 3.9 Codon optimized sequence of the CpSADH gene. 
 
 
Figure 3.10 Codon optimized sequence of the PfODH gene. 
 
The CpSADH and PfODH enzymes were purified separately by FPLC with a 
Ni-NTA column. His-tagged CpSADH as well as his-tagged PfODH were 




Figure 3.11 SDS-PAGE of purified N-terminal histag CpSADH and PfODH. 
 
3.3.8 Kinetic Study of YAD, CpSADH and PfODH  
The kinetic parameters of his-tagged YAD, CpSADH and PfODH for the 
oxidation of 1-octanol, (S)-2-octanol, and (R)-2-octanol, were investigated 
respectively by using a NBT-PMS assay in the presence of NAD+. Reactions 
were performed with substrate concentration from 0.125 mM to 1.25 mM in the 
present of 1 μM of YAD, CpSADH and PfODH, respectively, and the Km and 
Vmax values of each enzyme were obtained from the Lineweaver-Burk plot 
(Figure 3.12 and Table 3.5).   
       






















Figure 3.12 Lineweaver-Burk curves of PfODH-catalysed oxidation of (R)-2-octanol, 
CpSADH-catalysed oxidation of (S)-2-octanol, and YAD-catalysed oxidation of 1-octanol. 
 
Table 3.5 Kinetic data for oxidation of 1-octanol, (R) and (S)-2-octanol catalysed by YAD, 
PfODH and CpSADH, respectively. 
 
 
3.3.9 Validation of the Regio- and Enantioselective colorimetric 
HTS assay  
In the literatures, the authors mentioned that CpSADH and PfODH were highly 
specific to the (S)- and (R)-2-octanol and displayed no activity towards 1-

















Lineweaver-Burk method for CpSADH


















Lineweaver-Burk method for YAD
Substrate Enzyme Km [μM] Vmax [μM/min] Kcat [1/min] 
1-octanol YAD 127 23 23 
(S)-2-octanol CpSADH 143 39 39 
(R)-2-octanol PfODH 158 18 18 
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octanol. To confirm this phenomenon and to evaluate the accuracy and 
sensitivity of our assay under complex conditions, we prepared several samples 
containing different mixtures of (S)-/(R)-2-octanol and 1-octanol. We assayed 
each sample with purified CpSADH and PfODH separately, coupled with the 
NBT-PMS assay.  
 
 
Figure 3.13 Validation of the colorimetric HTS assay. (a) OD580 values measured for the 
oxidation of the first group samples with YAD, CpADH, and PfODH, respectively. (b) Linear 






As shown in Figure 3.13(a), the UV absorption was proportional to the 
concentration of 1-octanol, (S)-2-octanol, and (R)-2-octanol, respectively. The 
determined concentration of 2-octanol and ee of (S)-2-octanol were very close 
to the real values of these compounds in the mixture samples. As shown in 



















Correlation between Y value and ee















to the real ee values of these compounds in the mixture samples. More 
importantly, all of these values were independent from the total concentration 
of the samples. 
3.3.10 Directed Evolution with Real Substrate-based Regio- and 
Enantioselective Colorimetric HTS Assay 
The mutant library creation, mutants’ growth and protein induction procedures 
involved here were as same as that of the previous three rounds of mutagenesis. 
P450pyr (N100S/F403L/T186I) was used as template to generate a library of 
mutants for the 4th round of evolution, and the remaining 19 target residues were 
to be subjected to mutagenesis respectively. After screening a total of around 
3500 variants, one interesting mutant, P450pyr(N100S/F403L/T186I/L302V), 
with very good regio- and enantioselectivity was identified. As shown in the 
Figure 3.14, based on the GC and chiral GC analysis, this mutant significantly 
increased the subterminal selectivity of n-octane to 92% and gave (S)-2-octanol 
with 72% ee.  
Motivated by the great improvement in the fourth round, the fifth round of 
evolution was conducted, and the best mutant in this round P450pyr 
I83F/N100S/F403I/T186I/L302V, displayed > 99 % subterminal selectivity 
with 95 % (S)-enantioselectivity of n-octane. Finally, an excellent mutant was 
created from the sixth round, P450pyr A77Q/I83F/N100S/F403I/T186I/L302V 
(P450pyrSM1), which gave > 99% subterminal selectivity and 98% (S)-
enantioselectivity (Figure 3.15). All the key results of total six rounds of 
directed evolution was summarised in Table 3.6. 
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Figure 3.14 Chromatogram of biohydroxylation of octane by recombinant E. coli P450pyr 
mutant [P450pyr(N100S/L302V/F403L/T186I)] with (a) normal GC and (b) chiral GC. 
 
 
Figure 3.15 Chromatogram of biohydroxylation of octane by recombinant E. coli P450pyr 
mutant [P450pyr(A77Q/I83F/N100S/F403I/T186I/L302V)] with (a) normal GC and (b) chiral 
GC. 
 
Table 3.6 Directed evolution of P450pyr hydroxylase for regio- and enantioselective 
subterminal hydroxylation of n-octane to (S)-2-octanol. 
 
[a] Subterminal selectivity of the best mutant in each round was determined by GC analysis of 
the products from the biotransformation of 5 mM n-octane with 2 g cdw/L of E. coli cells 
expressing the P450pyr mutant in 10 mL potassium phosphate buffer (100 mM; pH 8.0) 
containing 2% (w/v) glucose at 30 oC and 250 rpm for 4 h.  [b] ee of (S)-2-octanol was 
determined by chiral GC analysis of the products from the biotransformation described in [a]. 
[c] Activity is the specific activity determined for the first 30 min of the biotransformation 
described in [a]. [d] Activity refers to the activity of E. coli cells expressing P450pyr for the 




3.3.11 Evaluation of New Developed Colorimetric HTS Assay 
An example of using new developed colorimetric HTS assay to determine the 
regio- and enantioselectivity of P450pyr mutant (N100S/T186I/L302V/F403I) 
in the fourth-round screening was listed in Figure 3.16. Based on the Equation 
(1) and Equation (2) from Figure 3.8 and the absorbance at OD580 in Figure 3.16, 
the estimated subterminal selectivity and enantioselectivity(S) of this mutant 
based on HTS is 91 % and 70 % respectively. Compared to the real regio- and 
enantioselectivity data from Figure 3.14 (subterminal selectivity = 92 %; 
enantioselectivity(S) = 72 %), the results estimated from colorimetric assay 
were very close and equivalent, which also indicated that our new developed 
three-enzymes based colorimetric regio- and enantioselective HTS screening 
assay had a very good accuracy.  
  
Figure 3.16 Using the colorimetric HTS assay to determination the regio- and enantio-
selectivity of P450pyr mutant (N100S/T186I/L302V/F403I) for the hydroxylation of n-octane.  
 
3.3.12 Cell Growth and Specific Activity of Recombinant E. coli 
(P450pyrSM1)  
Recombinant E. coli (P450pyrSM1) was grown in TB medium, and the 
expression of P450pyr monooxygenase was induced by adding 500 μM of IPTG 
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and 500 μM of ALA. As shown in Figure 3.17, a cell density of 4.0-4.5 g cdw/L 
was researched after 10 h. Cells taken at different time points showed different 
hydroxylation activity toward n-octane. The highest specific activity was 
observed for cells grown after 7 h, in the middle of exponential grow phase. 
Thus, harvested cells at this time point were used in the following 
biohydroxylations. 
 
Figure 3.17 Cell growth and specific activity for the hydroxylation of n-octane of E. coli 
(P450pyrSM1). Cells were initially grown at 37 °C for 2 h, induced by the addition of IPTG 
and ALA, and then grown at 22 °C. 
 
3.3.13 Kinetic Study of wild-type P450pyr and P450pyr SM1 
The his-tagged P450pyrSM1 was cloned, expressed and purified according to 
the method described previously for his-tagged P450pyr.  To study the kinetics, 
5 μM of purified his-tagged wild-type P450pyr and P450pyrSM1 were, 
respectively, mixed with excess Ferredoxin (Fdx) and Ferredoxin reductase 
(FdR) in 100 mM phosphate buffer (pH 8.0) containing 2% (w/v) glucose. 
Biotransformation of n-octane at different concentration (0.125-1.25 mM) in the 
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presence of 2 mM NADH was performed at 30 oC and 300 rpm for 30 min. The 
product (1-octanol or 2-octanol) concentration was determined by GC analysis, 
and the results were shown in Figure 3.18 and Table 3.7. 
    
 
Figure 3.18 Lineweaver-Burk curve of the hydroxylation of n-octane with his-tagged P450pyr 
and his-tagged P450pyr SM1. 
 
Table 3.7 Kinetic data of wild-type P450pyr and P450pyrSM1 for the hydroxylation of n-octane  
 Km (mM) Vmax (μM/min) kcat (1/min) kcat/Km(1/min.mM) 
WT P450pyr 3.583 54.3 10.86 3.031 
P450pyrSM1  2.187 29.5 5.9 2.698 
 











































3.3.14 Improvement of Product Concentration with E. coli 
(P450pyrSM1-GDH)  
Although the mutant, A77Q/I83F/N100S/F403I/T186I/L302V, was found to 
have comparable activity to wild-type P450pyr for the biohydroxylation of n-
octane, the produced alcohol concentration still not satisfied. In order to make 
our P450pyr mutant as an efficient biocatalyst, we aim to improve its activity 
by following our previously reported procedure for P450pyrTM - adding 
glucose dehydrogenase (GDH) to our current cofactor regeneration system.  E. 
coli (P450pyrSM1-GDH) co-expressing P450pyrSM1 monooxygenase and a 
glucose dehydrogenase (GDH) was engineered. The cells were grown and used 
for biohydroxylation in the same procedures described for E. coli 
(P450pyrSM1). As illustrated in Figure 3.19, the new constructed recombinant 
with cofactor recycling system improved product yield by 1.7 times. 
 
Figure 3.19 Time course of the formation of (S)-2-octanol in the biohydroxylation of 10 mM 
n-octane with resting cells of E. coli BL21(DE3) (P450pyrSM1 with or without GDH) in K 
buffer (100 mM; pH 8.0) containing glucose (2%; w/v) at 30 oC; pRSFDuet-P450pyrSM1 + 




3.3.15 Molecular Dynamics and Docking Simulation 
To understnd the stereochemistry outcome, the hydroxylation of n-octane with 
P450pyr and P450pyrSM1 were investigated by molecular dynamics and 
docking simulation. A reshaping of the binding pocket that is responsible for 
the subterminal and enantioselectivity was observed for the enzyme mutant. As 
shown in the Figure 3.20A, the binding pocket of P450pyr is very compact (9.3 
Å long, I102 to T259 and 7.1 Å wide, G255 to L302), the substrate stacks with 
a big hydrophobic cluster comprising of the northwest and south residues, and 
n-octane hence takes a vertical binding pose. The distance between the terminal 
C-H and the heme-O is the shortest (2.8 Å), giving rise to terminal 
hydroxylation (Figure 3.20C). In P450pyrSM1, the hydrophobic cluster is 
disrupted by the F403I and L302V mutation (Figure 3.20B). The binding pocket 
consequently extends southwards reaching 10.3 Å of width. The substrate 
adopts a horizontal binding pose along the heme plane, in north-south 
orientation. This special geometry of the binding pocket gives clearly catalytic 
preference to (S)-subterminal hydroxylation (Figure 3.20D): the distance 
between the subterminal C-HS and the heme-O is 2.7 Å, while the distance 




Figure 3.20 Substrate n-octane-P450pyr enzyme binding pose. (A) - (B): Top-view of the 
surface structure of (A) P450pyr and (B) P450pyrSM1. Hydrophobic clusters are shown in 
yellow. (C) - (D): Side view of the binding pose of (C) P450pyr and (D) P450pyrSM1. The 
distances between the heme-oxygen atom and the nearby hydroxgen atom of n-octane are 
denoted by dashed lines. 
 
3.3.16 Regio- and Enantioselective Hydroxylation of Propylbenzene 
The positive variants obtained in six rounds of evolution of P450pyr for the 
subterminal hydroxylation of n-octane were examined for the subterminal 
hydroxylation of propylbenzene to produce (S)-1-phenyl-2-propanol. The best 
mutant obtained from the 6th round, I83F/N100S/T186I/L251V/L302V/F403I 
(P450pyrSM2), gave 98% subterminal selectivity and 95% (S)-
enantioselectivity for the hydroxylation of propylbenzene. These selectivities 




Figure 3.21 Analysis of the products from regio- and enantioselective subterminal 




Regio- and enantioselective hydroxylation of non-activated carbon atoms is a 
useful reaction for the production of valuable compounds such as enantiopure 
alcohols and steroids. Compared with classical organic chemical method, the 
monooxygenase-catalysed hydroxylation is highlighted because it is more green, 
clean, selective and efficient. However, most monooxygenases show terminal 
selectivity, only P450BM-3 shows some subterminal hydroxylation activity, but 
the regio- and enantio-selectivity is poor. In this project, we solve this problem 
by engineering the P450pyr with directed evolution to create a set of new 
enzymes for enantioselective hydroxylation of non-activated carbon atoms at 
subterminal position. 
In this chapter, a terminal selective cytochrome P450pyr has been successfully 
evolved for the subterminal hydroxylation of alkane at non-activated carbon 
atom, giving a sextuple mutant P450pyrSM1 with excellent subterminal and 
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enantioselectivity towards n-octane and providing with the first enzyme for this 
type of highly selective alkane hydroxylation. This represents also the first 
success of fully altering the regioselectivity of a monooxygenase in 
biohydroxylation by evolution. Subterminal hydroxylation with the engineered 
P450pyr hydroxylase allows for regio- and enantioselective functionalization of 
alkane, a useful and challenging reaction in classic chemistry.  P450pyrSM1 
catalyses the hydroxylation of n-octane to produce (S)-2-octanol in 98% ee 
with >99 % subterminal selectivity. Another sextuple mutant P450pyrSM2 
hydroxylates propylbenzene to give (S)-1-phenyl-2-propanol in 95% ee with 98 % 
subterminal selectivity. Both subterminal alcohols (S)-2-octanol and (S)-1-
phenyl-2-propanol are useful and valuable intermediates for chemical and 
pharmaceutical synthesis. A novel, accurate, sensitive, and simple colorimetric 
HTS assay is developed for measuring both regioselectivity and 
enantioselectivity for a hydroxylation reaction. This provides with a solid basis 
for the successful evolution of regio- and enantioselective P450pyr hydroxylase 
for subterminal hydroxylation. The colorimetric HTS assay could be generally 
applicable for the discovery of other type of regio- and enantioselective 
enzymes for hydroxylations. The molecular modelling on the hydroxylations of 
n-octane with P450pyr and P450pyrSM1 mutant gives insight into the structure 
basis and the role of key mutations for fully altering the terminal selectivity to 
subterminal selectivity and gaining excellent enantioselectivity. The general 
knowledge and information obtained might be useful for guiding future 




 Chapter 4: Evolving P450pyr Monooxygenase for Highly 
Regioselective Terminal Hydroxylation of n-butanol to 
1,4-butanediol 
4.1 Introduction  
1,4-butanediol is a very important and useful chemical that is used 
predominantly as intermediate to synthesise a wide variety of chemical 
compounds.272-274 It is able to react with many different bifunctional reagents to 
produce different types of polymers, e.g. polyurethane and polybutylene 
terephthalate.275-277 It could also be further converted to gamma butyrolactone 
(GBL) and gamma hydroxybutanoic acid (GHB), both of which are important 
feedstock for the production of various valuable pharmaceuticals and fine 
chemicals.272-274 Attributed to the continuous expansion in manufacturing 
polymers, fine chemicals and pharmaceuticals, the global demand for 1,4-
butanediol grows steadily over the years. The global demand was approximately 
2.4 million tonnes in 2010, and is expected to grow at an annual growth rate of 
5% from 2012 to 2018.278 Currently, 1,4-butanediol is produced from petrol 
chemicals involving multi-step synthesis, high temperature and pressure, and 
the generation of toxic and flammable by-products and carbon footprint.279-281  
We are interested in developing a green and sustainable route to produce 1,4-
butanediol directly from n-butanol, which can be produced by fermentation 
from renewable resource,282,283 via hydroxylation. Thus far, no chemical- or bio-
catalyst has been reported for this reaction with the exception of a CYP153 
application under high pressure described in patent application WO 
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2014079683 A1 from Evonik Industries describing the principal feasibility of 
this oxidation from alkanes to terminal diols by a CYP153 enzyme.284 Although 
many monooxygenases, such as P450,120-122 sMMO,123,124 and alkB,125,126 were 
known for the hydroxylation of alkanes, only two cytochrome P450 enzymes, 
CYP153A16 from Mycobacterium marinum and CYP153A P. sp. from 
Polaromonas sp. strain JS666, were reported for the ω-hydroxylation of C8-C12 
primary alcohols, demonstrating the potential for P450s to catalyse terminal 
hydroxylation of alcohols.107 While CYP153A P. sp. could only oxidise 1-
octanol and 1-nonanol to the corresponding α,ω-diols with very low yields, 
CYP153A16 was able to ω-hydroxylate C8-C12 primary alcohols, displaying 
highest activity for 1-nonanol with 46.5% conversion.  However, the selectivity 
of these enzyme are both poor, with only 40–58 % and 74-96 % of the product 
was corresponding α,ω-diols, and the rest consisted of aldehydes, fatty acids 
and some other by-products. Besides, both enzymes do not show any 
hydroxylation activity toward small alcohols.107 Directed evolution has become 
a useful tool for engineering enzymes with new substrate acceptance, improved 
activity, regio-, and stereo-selectivity, or enhanced enzyme stability.18,285,286  
Here we reported the development of the first enzyme for highly regioselective 
terminal hydroxylation of n-butanol to 1,4-butanediol by directed evolution of 
P450pyr monooxygenase.  
As mentioned above, P450pyr from Sphingomonas sp. HXN-200, a class I P450 
monooxygenase, is able to catalyse the regio- and stereoselective 
hydroxylations.189-191 Directed evolution of P450pyr was also successfully 
performed to achieve excellent enantioselectivity for the hydroxylation of N-
benzylpyrrolidine,226,227 as well as excellent regio- and enantioselectivivity for 
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the subterminal hydroxylation of alkanes in Chapter 3. Although the substrate 
scope of P450pyr is diverse, including n-alkanes, cyclic alkanes and N-
heterocycles, it is still limited to medium-sized hydrophobic substrates, and 
initial experiments showed that P450pyr did not accept n-butanol as the 
substrate for any hydroxylation. Thus, the target of this project was to create 
new P450pyr enzymes for terminal hydroxylation of n-butanol by switching the 
substrate acceptance from a hydrophobic to hydrophilic compound (Figure 4.1). 
 
Figure 4.1 P450pyr Monooxygenase-catalysed regioselective terminal hydroxylation of n-
butanol to 1,4-butanediol. 
 
In order to achieve this goal, we first developed a colorimetric HTS assay for 
the enzyme directed evolution. It was a very difficult task, because both 
substrate and product are small colourless molecules with no UV absorbance 
and no distinguishing functional difference. To solve all these problems, instead 
of a real substrate-based HTS assay we developed a surrogate substrate-based 
colorimetric HTS method in this project.  The new developed HTS assay would 
be used to investigate all the P450pyr mutants which were generated from ISM 
based on n-butanol-P450pyr docking structure model analysis. All the good 
mutants identified from this surrogate substrate-based HTS would be tested with 
actual substrate n-butanol and analysed with various analytical tools. Several 
rounds of directed evolution would be performed and mutants which capable of 
producing 1,4-butanediol directly from n-butanol would be created and 
identified. Besides, the roles of the mutated amino acid residues on changing 
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the substrate scope and creating activity toward hydrophilic molecules would 
also be investigated based on simulation modelling and docking structure, 
which gave us a better understanding of the relationships between substrate 
scope and structure of P450pyr and its mutants. 
 
4.2 Experimental Section 
4.2.1 Chemicals 
Following chemicals were purchased from Sigma-Aldrich and used without 
further purification:  2-methoxyethanol (≥ 99 %), n-butanol (≥ 99 %), 1,2-
butanediol (≥ 98 %), 1,3-butanediol (≥ 99 %), 1,4-butanediol (≥ 99 %), purpald 
(≥ 99 %),  δ- aminolevulinic acid hydrochloride (ALA) (≥ 97 %), Isopropyl β-
D-1-thiogalactopyranoside (IPTG) D-Glucose (≥ 99.5%), dimethylformamide 
(DMF) (≥ 99 %), ethanol (≥ 99 %), ammonium sulphate (≥ 99 %), BSTFA 
(contains 1% TMCS, 99%), Sodium phosphate dibasic (≥ 99 %), and Sodium 
phosphate monobasic (≥ 99 %). 
4.2.2 Strains and Biochemicals 
Escherichia coli BL21(DE3) strain was purchased from Novagen. Plasmids 
pRSFDuet-P450pyr and pETDuet-Fdx-FdR were obtained from our own 
laboratory collections. Restriction enzyme Dpn I, Deoxynucleotide (dNTP) 
Solution Mix, and Q5 Hot Start High-Fidelity DNA Polymerase were purchased 
from New England Biolabs (NEB). Tris-acetate-EDTA (TAE) buffer, DNA 
loading dye, and DNA ladder were purchased from Thermo Scientific. 
Oligonucleotides were synthesised by AIT biotech, Singapore. LB Broth, Bacto 
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Yeast Extract, and Bacto Tryptone were purchased from Biomed Diagnostics. 
Antibiotic ampicillin and kanamycin were purchased from Sigma-Aldrich. 
QIAquick Gel Extraction Kit (Qiagen) and QIAprep spin plasmid miniprep Kit 
were purchased from Qiagen. 
4.2.3 Generation of P450pyr Monooxygenase Mutant Library 
To generate P450pyr monooxygenase mutant library, PCR was carried out on 
each of the selected amino acid site for ISM using the designed primers shown 
in Table 4.1. Each PCR reaction tube contained the following mixture: 2.5 µL 
forward and reverse primers of a particular target site, 10 µL Q5 reaction buffer, 
1 µL 10 mM dNTP mixture, 0.5 µL (10 ng) template DNA, 0.5 µL Q5 Hot Start 
High-Fidelity DNA polymerase and 33 µL of nuclease-free H2O. PCR 
amplification was carried out on Bio-Rad S1000 Thermal Cycler using the 
following thermal cycling program: 98 °C for 30 s, 25 cycles [98 °C for 10 s, 
annealing temperatures for each pair of primers (see Table S1 Tm*) for 30 s, 
72 °C for 3 min], and 72 °C for 5 min. 
 
Table 4.1 Primer sequences used for site-directed mutagenesis 




A77-F C TCG TCC GAT NNK GGA TAT GGC G 
69 
A77-R C GCC ATA TCC MNN ATC GGA CGA G 
I82 
I82-F GGA TAT GGC GGC NNK ATA ATC GAT GAC 
69 
I82-R GTC ATC GAT TAT MNN GCC GCC ATA TCC 
I83 
I83-F GGC GGC ATC NNK ATC GAT GAC G 
70 
I83-R C GTC ATC GAT MNN GAT GCC GCC 
I88 
I88-F C GAT GAC GGC NNK CAA AAA GG 
65 
I88-R CC TTT TTG MNN GCC GTC ATC G 
Q89 
Q89-F GAC GGC ATT NNK AAA GGT GGC G 
68 
Q89-R C GCC ACC TTT MNN AAT GCC GTC 
L98 
L98-F GC GGA CTG GAT NNK CCC AAT TTC 
67 
L98-R GAA ATT GGG MNN ATC CAG TCC GC 
P99 
P99-F GGA CTG GAT CTT NNK AAT TTC ATC GCG 
67 
P99-R CGC GAT GAA ATT MNN AAG ATC CAG TCC 
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a   N represents any possible bases and K represents either guanine (G) or thymine (T)    
b Tm* is the value of optimal annealing temperatures calculated with NEB Tm Calculator 
https://www.neb.com/tools-and-resources/interactive-tools/tm-calculator 
 
PCR products were subjected to DNA gel electrophoresis and the location of 
DNA in gel was detected using gel imaging system. The product band was 
excised from the gel and then purified using QIAquick Gel Extraction Kit 
(Qiagen). The purified DNA was digested with methylated restrictive enzyme 
Dpn I at 37°C overnight. P450pyr mutant library was created by transferring the 
digested DNA into competent E. coli BL21(DE3) cells containing the pETDuet-
Fdx-FdR vector. According to the ISM theoretical calculations, a total of 94 
mutant clones are required for each amino acid residue to have 95% coverage 
of all 20 possible amino acids. Therefore, 188 clones for each site were taken to 
N100 
N100-F G GAT CTT CCC NNK TTC ATC GC 
63 
N100-R GC GAT GAA MNN GGG AAG ATC C 
I102 
I102-F CCC AAT TTC NNK GCG ATG GAT C 
65 
I102-R G ATC CAT CGC MNN GAA ATT GGG 
A103 
A103-F CC AAT TTC ATC NNK ATG GAT CGG CC 
68 
A103-R GG CCG ATC CAT MNN GAT GAA ATT GG 
S182 
S182-F CTT ACC CGC NNK TCG GAT GTG AC 
69 
S182-R GT CAC ATC CGA MNN GCG GGT AAG 
D183 
D183-F GC TGG TCG NNK GTG ACA ACC 
67 
D183-R GGT TGT CAC MNN CGA CCA GC 
T185 
T185-F G GAT GTG NNK ACC GCA GC 
64 
T185-R GC TGC GGT MNN CAC ATC C 
T186 
T186-F GAT GTG ACA NNK GCA GCA CC 
64 
T186-R GG TGC TGC MNN TGT CAC ATC 
L251 
L251-F GTA CTT NNK CTG ATC GTT GGC G 
64 
L251-R C GCC AAC GAT CAG MNN AAG TAC 
V254 
V254-F C CTG ATC NNK GGC GGG AAC 
67 
V254-R GTT CCC GCC MNN GAT CAG G 
G255 
G255-F C CTG ATC GTT NNK GGG AAC G 
64 
G255-R C GTT CCC MNN AAC GAT CAG G 
D258 
D258-F C GGG AAC NNK ACC ACA CG 
64 
D258-R CG TGT GGT MNN GTT CCC G 
T259 
T259-F C GGG AAC GAT NNK ACA CGC 
64 
T259-R GCG TGT MNN ATC GTT CCC G 
L302 
L302-F G CAA ACA CCG NNK GCT CAT ATG C 
68 
L302-R G CAT ATG AGC MNN CGG TGT TTG C 
M305 
M305-F CTT GCT CAT NNK CGC CGC ACG 
71 
M305-R CGT GCG GCG MNN ATG AGC AAG 
F403 
F403-F CGT TCA AAT NNK GTG CGC GG 
66 
F403-R CC GCG CAC MNN ATT TGA ACG 
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two 96-deep well plates in our experiment to ensure the coverage of > 95% for 
all possible 20 amino acids.    
4.2.4 General Procedure of Screening P450pyr mutants for 
Terminal Hydroxylation of Alcohol by Using Surrogate Substrate-
Based Colorimetric HTS Assay 
The generated P450pyr mutants were picked from LB agar plate and inoculated 
into 96-deep well plate with 600 µL TB medium containing 50 µg/mL 
kanamycin and 100 µg/mL ampicillin. The deep-well plate was shaken at 900 
rpm and 37 °C for 8 h. 100 µL cell cultures were taken out and mixed with 100 
µL 50% glycerol to prepare cell stock which was stored in -80 °C refrigerator. 
After that, 800 µL TB medium containing 0.5 mM IPTG, 0.5 mM ALA, 50 
µg/mL kanamycin and 100 µg/mL ampicillin were added to the remaining cell 
cultures in each well to induce the P450pyr protein expression. After expressing 
at 22 °C for 8 h, E. coli cells were harvested by centrifugation at 3220 g and 
room temperature for 15 min. 500 µL 100 mM potassium phosphate buffer (pH 
8.0) containing 2 % (w/v) D-glucose and 5 mM 2-methoxyethanol were added 
to the cell pellets in each well. The biotransformation was performed at 900 rpm 
and 30 °C for 4 h and stopped by centrifugation at 3220 g for 10 min.  
100 µL aliquot from each well were transferred to a microliter plate that 
contained 50 µL aqueous solution of 1 M NaOH and 100 mM purpald. After 
incubating at room temperature for 10 min, the absorbance of each well was 
measured at 550 nm using spectrophotometer (Thermo Scientific Multiskan Go). 
Mutants with hydroxylation activity towards the surrogate substrate 2-
methoxyethanol will produce formaldehyde, which react with purpald to give 
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purple colour compound. The principle of this surrogate substrate-based 
colorimetric HTS assay was shown in Figure 4.64.2A. The general procedure of 
this assay was shown in Figure 4.2B.  
 
Figure 4.2 The principle and procedure of surrogate substrate-based HTS assay. A) Principle of 
surrogate substrate-based colorimetric HTS assay B) Procedure of screening E. coli (P450pyr 
mutants) for the terminal hydroxylation of n-butanol by using surrogate substrate-based 
colorimetric HTS assay. 
 
4.2.5 General Procedure for Biohydroxylation of n-butanol with 
E.coli Expressing Positive P450pyr Mutants in Shaking Flask 
E. coli strains containing positive P450pyr mutants were inoculated into 50 mL 
TB containing 50 µg/mL kanamycin and 100 µg/mL ampicillin in multiple 
shaking flasks, respectively. The mixtures were shaken at 250 rpm and 37 °C 
until OD600 researched 0.8. The proteins expression were induced by adding 
IPTG and ALA to a final concentration of 0.5 mM, respectively, and the mixture 
was shaken for additional 6 h at 250 rpm and 22 °C.  
The cell pellets were collected by centrifugation at 3220 g and room temperature 
for 10 min. The cell were resuspended to a density of 24 g cdw L-1 in 10 mL 
100 mM potassium phosphate buffer (pH 8.0) containing 2 % (w/v) D-glucose 
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and 5 mM of n-butanol. Biotransformation was performed at 300 rpm and 30 °C 
for 4 h, and the formation of 1,4-butanediol was analysed by GC. 
4.2.6 GC Analysis of 1,4-butanediol 
GC analysis was performed by using Agilent GC 6890 with Agilent HP-
INNOWAX column (25 m × 0.32 mm) in splitless injection mode with inlet 
temperature of 280 °C and detector temperature of 220 °C. Temperature 
program: 60 °C for 3 min, increased to 180 °C at 30 °C/min, and further 
increased to 220 °C at 20 °C/min. Retention times: 6.86 min for 2-hexnaol 
(internal standard), 8.58 min for 1,2-butanediol, 8.93 min for 1,3-butanediol, 
and 9.47 min for 1,4-butanediol.  
To analysis the biotransformation mixture, the supernatant was first 
concentrated at room temperature with Eppendorf Concentrator Plus. 32 % 
(w/w) ethanol and 16 % (w/w) ammonium sulfate were then added to the 
concentrated supernatant to form two-liquid phases to extract 1,4-butanediol 
into ethanol phase. 100 µL ethanol phase were taken and used for GC analysis. 
4.2.7 MS Analysis of the Derivative of 1,4-butanediol Made by 
BSTFA-TMCS Method  
To further confirm the identity of the biotransformation product is 1,4-
butanediol, the mixture from biohydroxylation of n-butanol was derivatised by 
BSTFA-TMCS method. 1 mL biotransformation supernatant was dried at 45 °C 
with Eppendorf Concentrator Plus, followed by the addition of 20 µL DMF and 
100 µL BSTFA-TMCS regent. The derivatisation reaction was conducted at 
70 °C for 30 min. The derivatised mixtures were centrifuged at 20376 g for 5 
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min, and finally 60 µL sample was used for GC-MS analysis.  Similarly, the 
standard 1,4-butanediol was derivatised by using the same procedure.  
GC-MS analysis was performed using Agilent GC-MSD system 6890-5973A 
with GC-MSD HP-5 MS column in splitless injection mode with inlet 
temperature of 250 °C and the MS interface transfer line temperature of 270 °C. 
Temperature program: 80 °C for 1.5 min, increased to 140 °C at 10 °C/min,  
hold at 140 °C for 3 min, increased to 300 °C at 100 °C/min and hold at 300 °C 
for 5 min. Retention time for the derivatised (1,4-butanediol bis 
(trimethylsilyl)ether ) is 6.25 min. 
4.2.8 Molecular Modelling of Substrates Docking in P450pyr and Its 
Mutants   
The structure of P450pyr was obtained based on x-ray structure and enhanced 
using MODELLER287 via CHIMERA288 interface to supplant seven non-critical 
missing residues via the high precision Discrete Optimized Protein Energy score 
(DOPE-HR) algorithm.289 Amino acid residue mutations were performed via 
ACCELRYS Discovery Studio. Ramachandran plots for P450pyr, P450pyr 
I83M and P450pyrI83M/I82T models were generated before and after 
molecular dynamics (MD) simulations, and all revealed > 90 % of residues 
within allowed regions.  
MD simulations of wild type and mutant enzymes were all conducted with 
GROMACS 4.5290 using GROMOS 53a6 force field at a 0.2 ps recording 
interval in a water system with 150 mM NaCl. Long‐range electrostatic 
interactions were modelled via Particle Mesh Ewald (PME) method, and short 
range van der Waals interactions were localized at 10 Å. Bond lengths were 
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constrained via LINCS algorithm.291 Energy minimization was performed with 
Steepest descent algorithm, in which V-rescale thermostat and Parrinello-
Rahman barostat were used to stabilize temperature at 300 K and pressure at 1 
atm, respectively. 5 ns production runs coupled to NPT were conducted, and the 
recorded enzyme conformers were clustered using Gromos algorithm with 
RMSD cutoff at 0.18 nm.292 The main cluster centroids were docked with n-
butanol using Autodock VINA,293,294 where the catalytic heme was modified as 
the Cpd I ferryl-oxo-complex state.120 Docking results were evaluated via 
binding energy scores with docked clustering at 1 Å non-fitted RMSD cutoff. 
Catalytically relevant active binding postures for terminal hydroxylation of n-
butanol required the terminal substrate-C to be at closest approach to heme-O 
atom at a distance of < 6 Å, and also with Fe-O-H angles in the optimal range 
of 110o to 160o as part of established geometric criteria for substrate-heme 
binding in P450 enzymes. 295,296 
 
4.3 Results and Discussion 
4.3.1 Development of Colorimetric HTS Method 
In this project, develop a suitable colorimetric HTS assay for discovery of 
P450pyr mutants for terminal hydroxylation of n-butanol was indeed a 
challenge. There is no distinguishing functional difference between n-butanol 
and 1,4-butanediol except for the one more -OH group, neither the substrate nor 
the product are UV or fluorescence sensitive, and no enzyme or chemical 
catalyst were reported to react with butanol or 1,4-butanediol exclusively. 
Therefore, using a surrogate substrate instead of real substrate would be a more 
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practical choice, so far many enzymes have already been successfully 
engineered by using surrogate substrates.297 
After extensive literature search, a surrogate substrate, 2-methoxyethanol, was 
selected to carry out the assay in place of n-butanol. As illustrated in Figure 
4.3A, terminal hydroxylation of 2-methoxyethanol produced an unstable 
hemiacetal functional group, which is unstable would quickly become 
formaldehyde and ethylene glycol. The amount of produced formaldehyde 
would further react with an uncoloured compound, purpald, to produce an 
intense purple product in the presence of air within 10 minutes. Although 
purpald could react with both aldehydes and ketones, only the reaction with 
aldehydes could produce a coloured production, reaction with ketones produces 
a colourless product because it cannot undergo further oxidation to form an 
extended heterocyclic conjugated system.  
The performance of the assay was determined by standard calibration. It was 
found that the assay produced good linearity and excellent sensitivity from 0.05 
mM to 1 mM within 10 minutes (Figure 4.3B and Figure 4.3C). This proved the 
effectiveness of the assay as an efficient and sensitive method to quantify the 
amount of formaldehyde present in a particular sample mixture.  
Purpald's reaction with various aldehydes proceeds at different rate, with 
formaldehyde completing the reaction within 10 minutes.298 Other aldehydes 
such as acetaldehyde or even the aldehyde group in open chain form of glucose 
proceed at a slower rate than formaldehyde. It is important to note that glucose 
is present in significant amount in the reaction mixture. 2 % w/v glucose is 
equivalent to about 100 mM concentration. This high concentration of glucose 
may interfere with the assay. An experiment was conducted to determine the 
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effect of 2% w/v glucose on the assay and it was found that the influence of 
glucose is insignificant until more than 2 hours after the addition of purpald. 





Figure 4.3. Principle and sensitivity of the colorimetric HTS assay using surrogate substrate 
and purpald. A) Principle of the colorimetric HTS assay for terminal hydroxylation of surrogate 
substrate. B) Calibration curve of the concentration of formaldehyde and the UV absorption at 
550 nm of purple compound produced by the treatment of formaldehyde and purpald. Data are 
the mean values with standard deviations of three replicates. C) Photos of purple  produced from 
formaldehyde at different concentration by the addition of purpald for 10 min. 
 
4.3.2 Identification of suitable amino acid residues of P450pyr for 
Iterative Saturation Mutagenesis (ISM) 
To identify the suitable amino acid residues for ISM, n-butanol was docked into 
the x-ray structure of P450pyr (PDB ID: 3RWL) with the catalytic heme 
modified as the Cpd I ferryl-oxo-complex. The catalytically relevant active 
binding posture for n-butanol was obtained based on established geometric 
criteria for substrate-heme binding in P450 enzymes.295 As shown in Figure 4.4, 
totally twenty two amino acids residues were selected for ISM. Elven amino 
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acids were located within ~6.5 Å of the docked substrate: (i) important 
hydrophobic residues: Ile82, Ile83, le102, Leu302, Met305, and Phe403; and (ii) 
residues on the heme-proximal helix: Leu251, Val254, Gly255, Asp258, and 
Thr259. Four amino acids located along another helix (Ser182, Asp183, Thr185 
and Thr186) were also chosen due to their relatively abrupt position in the 
substrate access channel. Seven important amino acids from the ‘big loop’ 
(Ala77, Ile88, Gln89, Leu98, Pro99, Asn100, and Ala103) were also chosen for 
ISM, since in our previous study an improvement in P450pyr enantioselectivity 
was attributed to a reshaped binding pocket via inward movement of this “big 
loop” (Ser74-Asp105).103  
 
Figure 4.4 Selection of suitable amino acid residues for ISM. (A) Spatial overview of 22 
selected amino acid residues for ISM, in relation to the active binding posture of n-butanol (grey 
cartoon stick with hydrogen atoms) in P450pyr. (B) Surface presentation of the same overview 
with additional structural motifs for a more aesthetic appreciation of the enzyme-substrate 
binding posture. 
 
4.3.3 Generation of P450pyr Monooxygenase Mutant Library 
The mutant library of each selected site was generated by site-saturation 
mutagenesis in which all possible 20 amino acids will be generated in the mutant 
library. Complementary primers were designed for each amino acid residue by 
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using NNK sequence with 9-12 nearby bases. N represents any possible bases 
and K represents either guanine (G) or thymine (T). Generally, there three 
advantages of using “NNK” sequence: firstly it covers all possible 20 amino 
acids; secondly the amount of analysis effort is greatly reduced with only 32 
possible codons; more importantly, the distribution of degenerate codons is 
more even in NNK.205    
PCR amplification was done using the designed primers shown in Table 4.5. In 
order to make the PCR efficiency, it is crucial to use the appropriate annealing 
temperature for each pair of primes. Figure 4.5 shows an example of PCR 
products of four different sites, the PCR product bands as well as primer dimers 
can be seen clearly in this image. 
 
Figure 4.5 Image of gel electrophoresis after PCR amplification. Site L98, P99, A77 and I82 
are shown. 
 
4.3.4 Screening of P450pyr Mutants by Using Surrogate 
Substrate-Based Colorimetric HTS Assay 
Figure 4.6 showed a sample 96-well plate that was in the process of colorimetric 
high-throughput screening assay. Mutants with high hydroxylation activity 
towards the surrogate substrate produce sufficient formaldehyde that showed an 
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intense purple colouration visible to naked eyes. Exact quantification of 
absorbance was performed with a spectrophotometer.   
 
Figure 4.6 A sample 96-well plate in the process of HTS assay (2nd round). 
 
4.3.5 Selection of Identification and Quantification Method for 1,4-
butanediol  
HPLC is generally used for analysing non-volatile chemicals, as well as proteins 
and amino acids. It is also widely used in identification and quantification of 
polar compounds to bypass the effort of samples extraction. For 1,4-butanediol, 
however, its structure is too simple and does not have conjugated system for 
UV detector, the most common HPLC detector. Though universal detectors 
such as refractive index (RID) detector are available, it is about 1000 times less 
sensitive compare with UV detector. Under our lab condition, the detection limit 
of 1,4-butanediol using RID is about 1 mM. As such, we consider HPLC 
analysis is not practical until the product concentration is high enough after 
several rounds of directed evolution. 
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GC is another frequently used analytical method for detection of organic 
molecules. Compare with HPLC, most GC columns are sensitive to moisture 
and thus GC analysis requires organic extraction since most biotransformation 
reaction are carried out in aqueous phase. Since 1,4-butanediol is a very 
hydrophilic compound, which is almost insoluble in most organic solvents such 
as chloroform and hexane, the organic extraction of 1,4-butanediol from 
biotransformation mixture is very challenge. An ideal organic solvent suitable 
to extract as much 1,4-butanediol as possible is the one with the highest relative 
polarity and lowest solubility in water. After an extensive literature search and 
testing with several organic solvents, including: cyclohexanol, ethanol, 1-
propanol, 1-butanol, 1-octanol and acetone, an ethanol-ammonium sulphate 
method adapted from Li et. al was identified as the most efficient system for 
1,4-butanediol extraction. 299  
 
4.3.6 Directed Evolution with Surrogate Substrate-based 
Colorimetric HTS Assay 
In the first round of evolution, all of the 22 selected amino acid positions were 
subjected to ISM. P450pyr variants were generated at each selected amino acid 
site by PCR using NNK degenerate codon. The digested DNAs were transferred 
into competent E. coli BL21(DE3) cells containing the pETDuet-Fdx-FdR 
vector. The created P450pyr variants were inoculated, grown, expressed, 
harvested, and subjected to the surrogate substrate-based colorimetric HTS 
assay on microtiter plate by the use of 5 mM 2-methoxyethanol and 4 h 
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biotransformation, treatment with NaOH and purpald for 10 min, and 
measurement of OD550 to determine the formation of purple product. 
After screening of 4136 clones, 234 clones were found to show an OD550* (after 
deduction with the OD vale from the wild-type enzyme) of >0.3 (Table 4.2). An 
example with P450pyr mutant I83M showing OD550* of 0.462 was given in 
Figure 4.7A. The 234 promising clones were selected for individual 
biotransformation of n-butanol on a 10 mL scale. The product after 4 h reaction 
was extracted and then analysed by GC. P450pyr mutant I83M was found to 
give the highest productivity with excellent regioselectivity for the terminal 
hydroxylation. 0.25 mM 1,4-butanediol were produced (Figure 4.7B), and no 
hydroxylation product at other position could be found in GC chromatogram. 
 
Table 4.2 Directed evolution of P450pyr hydroxylase for terminal hydroxylation of n-butanol 
















Wild-type Nil Nil Nil Nil 0 
1 22 4136 234 I83M 0.25 
2 21 3948 122 I83M/I82T 0.40 
a Surrogate substrate based colorimetric HTS assay was used. Clones gave product OD550* of > 
0.3 in the 1st round and of > 0.5 in the 2nd round were identified as promising clones. b All 
promising clones were tested for the biohydroxylation of n-butanol, and the formation of 
product was determined by GC analysis. c Biotransformation of 5 mM n-butanol was performed 
with the resting cells of E. coli (P450pyr or best mutant) (24 g cdw L-1) on 10 mL scale for 4 h. 
The product concentration was determined by GC analysis. 
 
The P450pyr mutant I83M was used as a template for the second round of 
evolution by ISM at the remaining 21 selected amino acid residues. In this round, 
only the 122 clones which gave OD550* of > 0.5 by using colorimetric HTS 
assay were selected for further investigation on the hydroxylation of n-butanol 
with GC analysis. P450pyr Mutant I83M/I82T was identified to produce 0.4 
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mM of 1,4-butanediol in 4 h biotransformation of n-butanol. As showed in 
Figure 4.7B, no by-product was formed, suggesting the excellent terminal 
hydroxylation selectivity. 
 
Figure 4.7 Photos and chromatogram of biohydroxylation of 2-methoxyethanol and n-butanol 
by recombinant E. coli P450pyr and its variants. A) Photos and OD550* values of the purple 
product from the biohydroxylation of surrogate substrate with E. coli (P450pyr) and its variants, 
respectively. OD550* = OD550 (P450pyr mutant) - OD550 (P450pyr). B) GC chromatograms of 
the product from biohydroxylation of n-butanol with E. coli (P450pyr), and its variants, 
respectively. 9: 2-hexanol (internal standard); 2: 1,4-butanediol; *:unrelated cell metabolite that 
existed also in the control samples where no transformation of n-butanol was observed. 
 
4.3.7 Comparison of Product Concentrations Determined by 
Colorimetric Assay and GC Analysis 
The comparison of using the P450pyr and its mutant I83M and I83M/I82T for 
the hydroxylation of surrogate substrate 2-methoxyethanol followed by 
colorimetric HTS assay and for the hydroxylation of n-butanol followed by GC 
analysis, respectively, was performed, and similar product concentration was 
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detected as shown in Figure 4.8. This suggested the surrogate substrate-based 
colorimetric HTS assay was reliable for the real screening. 
 
Figure 4.8 Comparison of product concentrations determined by colorimetric HTS assay as and 
GC analysis. 
 
4.3.8 MS Analysis of the Derivative of 1,4-butanediol Made by 
BSTFA-TMCS Method 
The biotransformation product from biohydroxylation of n-butanol with E. coli 
(P450pyrI83M), and E. coli (P450pyrI83M/I82T) were derivatised with 
BSTFA-TMCS to give 1,4-butanediol bis(trimethylsilyl)ether, and the MS 
analysis confirmed its structure. The retention time for the standard derivatised (1,4-
butanediol bis(trimethylsilyl)ether ) is 6.25 min. As shown in Figure 4.9, the MS peak 
of the derivatised biohydroxylation product peak at 6.25 min was as same as standard 
derivatised 1,4-butanediol, which further confirmed that the biotransformation 




Figure 4.9 MS analysis of peak at 6.25 min in the GC chromatogram for BSTFA-TMCS 
derivative of 1,4-butanediol. (A) derivative from standard 1,4-butanediol; (B) derivative from 
biotransformation product with induced cell of E. coli (P450pyrI83M). (C) Proposed 
fragmentation of the derivatised 1,4-butanediol.  
 
4.3.9 Molecular Modelling of Substrates Docking in P450pyr and its 
Mutants   
To explore the molecular basis of the observed hydroxylation reactions, in silico 
modelling of docking n-butanol in the X-ray structure of P450pyr and the 
structure models of P450pyr mutants I83M and I83M/I82T were performed, 
respectively. As shown in n-butanol-P450pyr binding conformation (Figure 
4.10A and 4.10D), the hydrophobic end of the substrate is located between the 
two hydrophobic residues Ile102 and Leu302 and the hydroxyl group of the 
substrate is oriented towards the hydrophilic Thr 259. In this conformation, the 
hydroxyl group is very close (2.0 Å) to the heme oxygen atom (heme-O), thus 
being inadequate for any hydroxylation activity.  
For the single mutant (Figure 4.10B and 4.10E), I83M introduced a longer 
residue Met83 which influences the nearby amino acid residues to give a shorter 
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distance between the two hydrophobic residues Ile102 and Leu302 (5.7 Å in 
I83M vs 8.5 Å in P450pyr). As a result, the hydrophobic end of the substrate 
cannot be located between Ile102 and Leu302 and thus took another orientation. 
The hydroxyl group of the substrate was still oriented towards the hydrophilic 
Thr 259 but far away from the heme-O. In this conformation, the distance 
between heme-O and C(2), C(3), and C(4) was 4.4 Å, 4.0 Å, and 3.7 Å, 
respectively, thus giving rise to the regioselective terminal hydroxylation of n-
butanol.  
For the double mutant (Figure 4.10C and 4.10F), I82T introduced a hydrophilic 
Thr82 residue, which removed the hydrophobic interaction between Ile82 and 
Ile102 and enabled the nearby hydrophilic residue Ser75 encroached upon the 
binding pocket. The hydroxyl group of the substrate was oriented towards the 
hydrophilic Ser75 and Thr82, and the hydrophobic end of the substrate was 
located close to heme-O, with a distance of 3.4 Å. This distance was shorter 
than the one for the single mutant I83M (3.7 Å), suggesting higher terminal 
hydroxylation activity for the double mutant I83M/I82T. In the substrate 
binding pose of the double mutant, the distance between heme-O and C(2) and 
C(3) was 4.8 Å and 5.4 Å, respectively, which explained the high 





Figure 4.10 Enzyme-substrate binding pose for n-butanol in P450pyr or mutant. A-C) Enzyme 
structures in cartoon ribbon style with mutated residues in yellow. A) P450pyr, B) P450pyr 
I83M, C) P450pyr I83M/I82T. D-F) Enzyme structures in surface style with hydrophobic 
residues in green and hydrophilic residues in red. D) P450pyr, E) P450pyr I83M, F) P450pyr 
I83M/I82T. Distances are denoted by a red dashed line. 
 
4.4 Conclusion 
P450pyr mutants (I83M and I83M/I82T) were successfully engineered by 
directed evolution to enable highly regioselective terminal hydroxylation of n-
butanol to produce 1,4-butanediol. To our knowledge, this is the first report of 
this hydroxylation reaction by either chemical or enzymatic method. Although 
the current enzyme mutant is not active enough for practical synthesis of 1,4-
butanediol from the bio-based n-butanol, our research provides with a solid 
basis for further engineering the enzyme to improve the activity. It is also an 
unique example of evolving a hydroxylase to switch the substrate acceptance 
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from hydrophobic to a hydrophilic compound. The surrogate substrate-based 
colorimetric HTS assay was proven to be useful and reliable for the screening 
of enzymes for the terminal hydroxylation of alcohol. Molecular docking 
provided some insight into the substrate binding pose, the reshaping of binding 
pocket by the mutations, and the role of key mutations for creating terminal 
hydroxylation activity and regioselectivity. This information could be very 
useful for further engineering more active mutants for terminal hydroxylation 
of n-butanol and potentially useful for switching substrate acceptance of a 





 Chapter 5.  Benzylic Hydroxylation of Fluoro- and Other 
Halo-Substituted Toluenes with Engineered P450pyr 
Monooxygenase 
5.1 Introduction 
Fluoro- and other halo-substituted benzyl alcohols are important and widely 
used intermediates for the productions of pharmaceuticals and fine chemicals, 
of pharmaceuticals, fine chemicals, agrochemicals.300-302 For instances: 2-
fluorobenzyl alcohol is an intermediate for synthesizing novel acid pump 
antagonists,303 and glucokinase activators.304 3-fluorobenzyl alcohol is useful 
for preparation of boron-containing antifungal agent for the potential treatment 
of onychomycosis305 and neuronal nitric oxide synthase inhibitors.306 4-
fluorobenzyl alcohol is the intermediate for C-2-symmetric diol-based HIV-1 
protease inhibitors307 and 2,4-diaminoquinazoline derivatives as SMN2 
promoter activators for the potential treatment of spinal muscular atrophy.308 
Currently, this group of compounds is mainly produced from pre-functionalised 
toluenes, which involving not only multi-steps of pre-function and also the 
generation of toxic and corrosive by-products such as HCl.309-311 Direct C-H 
bond activation of fluoro- and other halo-substituted toluenes presents the 
simplest route to produce their corresponding alcohols. Although tremendous 
progresses of C-H bond activation have been reported using transition-metal 
catalysts,312,313 to date only one catalyst cerium (IV) triflate was reported for the 
hydroxylation of benzylic aromatics.314 Nevertheless, this catalyst only showed 
excellent chemo- and regioselectivity toward 4-fluorotoluene, to other 
substrates (including 2-fluorotoluene, 2-chlorotoluene, 3-chlorotoluene), 
99 
 
however, the catalyst’s chemo- and regioselectivity and activity were relatively 
poor. Besides, this reaction also suffered from long reaction time, limited 
substrate scope, high catalyst loading, as well as requiring expensive and 
hazardous reactants.314  
On the other hand, nature offers an alternative and attractive solution for this 
reaction in the use of a monooxygenase, as a green and efficient catalyst and 
molecular oxygen from atmosphere as a cheap and green oxidant.121,315,316 
However, only very few monooxygenases have been reported for this type of 
reaction, and their catalytic performances (substrate acceptance, selectivity and 
activity) are unsatisfactory for industry applications. Xylene oxygenase from 
Pseudomonas putida is the first enzyme reported for this type of reaction, 
although a good activity was showed, its substrate scope was still limited, no 
activity toward 2-position substituted chloro- and bromotoluenes and no activity 
of any fluorotoluenes.109 p-cymene monooxygenase from Pseudomonas putida 
F1, however, was able to hydroxylate 4-fluorotoluene, 3-chlorotoluene and 4-
chlorotoluene, but the activity and conversion were extremely low.108 Recently, 
a double mutant of P450 BM3 was reported for the benzylic hydroxylation of 
some toluene derivatives, but with no activity toward bromo- and chlorotoluene, 
it showed activity toward 3-fluorotoluene, however no reliable measurement of 
the produced 3-fluorobenzyl alcohol.182  
We are interesting in developing new enzymes for the hydroxylation of fluoro- 
and other halo-substituted toluenes with high chemo- and regioselectivity to 
prepare useful and valuable alcohols. In this project, we explored the synthetic 
application of engineered P450pyr monooxygenases generated in chapter 3 and 
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4 for this challenge reaction. All the available P450pyr variants generated by 
directed evolution as well as the wild-type P450pyr were used for the enzymatic 
hydroxylation of 4-fluorotoluene first. The mutant which showed the best 
selectivity and highest activity towards 4-fluorotoluene would then be use for 
the hydroxylation of other fluoro- and halo-substituted toluenes. Moreover, the 
best mutant was also explored for the hydroxylation of multiple fluoro-
substituted toluenes since the hydroxylation of strong electron-withdrawing 
groups containing substrate is still problematic in classic chemistry.  In addition, 
the relationship between mutated amino acids and high benzylic hydroxylation 
activity were also investigated based on the simulation model and docking 
structure. The obtained information and knowledge is useful for further 
engineering of P450pyr for other hydroxylations and oxidations. 
 
5.2 Experimental Section 
5.2.1 Chemicals 
All of the following chemicals were purchased from Sigma-Aldrich and used 
without further purification: δ-aminolevulinic acid hydrochloride (ALA) (≥ 
97 %), Isopropyl β-D-1-thiogalactopyranoside (IPTG), D-Glucose (≥ 99.5%), 
Sodium phosphate dibasic (≥ 99 %), and Sodium phosphate monobasic (≥ 99 %), 
2-fluorotoluene (≥ 99 %), 3-fluorotoluene (99 %), 4-fluorotoluene (97 %), 2-
chlorotoluene (99 %), 3-chlorotoluene (98 %), 4-chlorotoluene (98 %), 2-
bromotoluene (99 %), 3-bromotoluene (98 %), 4-bromotoluene (98 %), 2-
fluorobenzyl alcohol (98 %), 3-fluorobenzyl alcohol (98 %), 4-fluorobenzyl 
alcohol (97 %), 2-chlorobenzyl alcohol (99 %), 3-chlorobenzyl alcohol (98 %), 
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4-chlorobenzyl alcohol (99 %), 2-bromobenzyl alcohol (99 %), 3-bromobenzyl 
alcohol (99 %), 4-bromobenzyl alcohol (99 %). 3,4-difluorotoluene (> 98.0 %), 
2,3,4,5,6-pentafluorotoluene (> 98.0 %), 3,4-difluorobenzyl alcohol (≥ 98 %) 
and pentafluorobenzyl alcohol (> 96.0 %) were purchased from Tokyo 
Chemical Industry. LB Broth, Bacto Yeast Extract, Bacto Tryptone were 
purchased from Biomed Diagnostics.  
5.2.2 Strains and Biochemicals 
Escherichia coli BL21(DE3) was used as host for enzyme expression. The 
recombinant E. coli (P450pyr) or E. coli (mutated P450pyr) with dual plasmids, 
pETDuet containing ferredoxin (Fdx) and ferredoxin  reductase (FdR) genes, 
and pRSFDuet containing P450pyr or mutated P450pyr gene, were  generated 
from directed evolution as described in chapter 3 and 4. Oligonucleotides were 
synthesised by AIT biotech, Singapore. LB Broth, Bacto Yeast Extract, and 
Bacto Tryptone were purchased from Biomed Diagnostics. Antibiotic 
ampicillin and kanamycin were purchased from Sigma-Aldrich. QIAquick Gel 
Extraction Kit (Qiagen) and QIAprep spin plasmid miniprep Kit were purchased 
from Qiagen. 
 
5.2.3 Analytical methods 
The concentrations of all the compounds (halo-substituted toluenes and their 
corresponding alcohols) were determined using a Shimadzu prominence HPLC 
system (reverse phase) with an Agilent Poroshell 120 EC-C18 column (150 × 
4.6 mm, 2.7 µm) and UV detection at 210 nm. HPLC analysis condition: 40% 
water with 60% acetonitrile. Flow rate: 0.4 mL/min.  Retention times of 
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different compounds were listed as follow: 12.4 min for 2-fluorotoluene and 5.8 
min for its alcohol; 12.3 min for 3-fluorotoluene and 5.8 min for its alcohol; 
12.2 min for 4-fluorotoluene and 5.7 min for its alcohol; 16.5 min for 2-
chlorotoluene and 6.5 min for its alcohol; 16.5 min for 3-chlorotoluene and 6.5 
min for its alcohol; 16.3 min for 3-chlorotoluene and 6.4 min for its alcohol; 
18.3 min for 2-bromotoluene and 6.8 min for its alcohol; 18.3 min for 3-
bromotoluene and 6.8 min for its alcohol; 18.2 min for 4-bromotoluene and 6.7 
min for its alcohol; 12.6 min for 3,4-difluorotoluene and 6.0 min for its alcohol; 
16.3 min for 2,3,4,5,6-pentafluorotoluene and 7.0 min for its alcohol. 
5.2.4 Biohydroxylation of 4-fluorotoluene with Resting Cells of 
Recombinant E. coli (P450pyr) and E. coli (mutated P450pyr) 
The recombinant E. coli BL21 (DE3) strains expressing P450pyr [E. coli 
(P450pyr)] or mutated P450pyr [E. coli (mutated P450pyr)] were inoculated 
respectively into 5 mL LB medium containing 50 mg/L of kanamycin and 100 
mg/L ampicillin. 2 mL overnight inoculum was transferred to 50 mL TB 
medium containing 50 mg/L of kanamycin and 100 mg/L ampicillin in a 250 
mL shaking flask. Cells were grown at 37°C and 250 rpm until OD 600 research 
0.6~0.8 and then induced by adding IPTG and ALA to a final concentration of 
0.5 mM. Cells were then grown at 22°C for another 12 h and then harvested by 
centrifugation at 5000 g for 5 min. The cells were re-suspended to a density of 
8 g cdw L-1 in 10 mL 100 mM potassium phosphate buffer (pH 8.0) containing 
2 % (w/v) D-glucose and 5 mM of 4-fluorotoluene. Biotransformation was 
performed at 300 rpm and 30 °C for 4 h, and the formation of 4-fluorobenzyl 
alcohol was analysed by reverse HPLC.  
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5.2.5 Cell Growth, Hydroxylation Activity and Protein Expression 
of E. coli (P450pyr3M) 
The cell growth and specific hydroxylation activities of the P450pyr3M at 
different time points were examined by using 4-fluorotoluene as substrate. The 
cell was grown in TB medium, and the expression of P450pyr monooxygenase 
was induced by adding 500 μM of IPTG and 500 μM of ALA. The induction 
was carried out at 22 oC for additional 8 h. Samples were taken at different time 
points for the determination of optical density at 600 nm. At the same time, 
induced cells were harvested and re-suspended for the hydroxylation of 4-
fluorotoluene for 30 min to examine the specific activity. A SDS-PAGE (12% 
resolving gel and 4% stacking gel) was applied to check the purity of the 
proteins.   
5.2.6 Biohydroxylation of Halo-toluenes with Resting Cells of 
Recombinant E. coli (P450pyr3M)   
The recombinant E. coli (P450pyr3M) was inoculated, grown, expressed and 
harvested as described above. For specific activity determination, the cells were 
resuspended to a density of 4 g cdw L-1 in 10 mL 100 mM potassium phosphate 
buffer (pH 8.0) containing 2 % (w/v) D-glucose, 10% DMSO and 10 mM of 
different halo-toluenes and reaction was performed at 300 rpm and 30 °C for 30 
min; while for product concentration and yield detection, the cells were re-
suspended to a density of 8 g cdw L-1 in 10 mL 100 mM potassium phosphate 
buffer (pH 8.0) containing 2 % (w/v) D-glucose, 10% DMSO and 5 mM of 




5.2.7 Biohydroxylation of 3-bromotoluene with resting cells of E. 
coli (P450pyr3M) 
The recombinant E. coli (P450pyr3M) was inoculated, grown, expressed and 
harvested as described above. The cell were re-suspended to a density of 8 g 
cdw L-1 in 10 mL 100 mM potassium phosphate buffer (pH 8.0) containing 2 % 
(w/v) D-glucose, 10% DMSO and 25 mM of different 3-bromotoluene. 
Biotransformation was performed at 300 rpm and 30 °C for 12 h.  
5.2.8  Molecular Modelling of Halo-Toluenes Docking in P450pyr 
and P450pyr3M 
The molecular dynamics and docking simulation were performed as described 
in Chapter 3 and 4. Ramachandran plots for wild-type P450pyr and P450pyr3M 
models were generated before and after MD simulations. The main cluster 
centroids were docked with halo-toluene substrates using Autodock 
VINA,293,294 with the heme set as ferryl-oxo-heme complex state known as Cpd 
I. Docking results were evaluated via the criteria of binding energy scores with 
docked-posture clustering via a 1 Å non-fitted RMSD cutoff. Catalytically 
relevant active binding postures of halo-toluene substrates were taken as those 
where substrate methyl-C was within a distance of < 6 Å from the heme-O atom, 
and also consistent with optimized geometric criteria for substrate-heme 




5.3 Results and discussion 
5.3.1 Biohydroxylation of 4-fluorotoluene with Resting Cells of 
Recombinant E. coli (P450pyr) and E. coli (mutated P450pyr) 
Totally 29 engineered P450pyr monooxygenases were generated in Chapter 3 
and Chapter 4 (Table 5.1).  The recombinant E. coli BL21 (DE3) strains 
expressing P450pyr or mutated P450pyr were all used for the biohydroxylation 
of 4-fluorotoluene. So far only one enzyme, p-cymene monooxygenase from 
Pseudomonas putida F1 was reported capable of direct hydroxylate 4-
fluorotoluene to 4-fluorobenzyl alcohol, however the activity and conversion 
was very low, only 3.5 μM of 4-fluorobenzyl alcohol was produced from 5 mM 
4-fluorotoluene after 3 hours.  
 
Table 5.1 P450pyr mutant library: mutant numbers and their corresponding mutations 
No. Mutant No. Mutant 
1 N100S 16 N100S/F403M 
2 N100S/F403I 17 N100S/M305Q 
3 N100S/F403I/T186I 18 N100S/F403I/M305Q 
4 N100S/F403I/T186I/L302V 19 N100S/F403I/T186I/M305Q 
5 N100S/F403I/T186I/L302V/I83F 20 N100S/F403I/T186I/L302V/M305Q 
6 N100S/F403I/T186I/L302V/I83F/A77Q 21 M305Q/T186I 
7 N100S/F403I/T186I/L302V/I83F/L251V 22 N100S/T186I/M305Q 
8 N100S/F403I/T186I/L302V/I83F/I102P 23 N100S/F403I/L302V 
9 I82S 24 N100S/F403I/T186I/L302V/T259A 
10 T185K 25 N100S/F403I/T186I/L302V/T259A/305Q 
11 T259A 26 N100S/F403I/T186I/D183E 
12 I83L 27 N100S/F403I/T185Y 
13 T185V 28 I83M 





Most of the P450pyr variants as well as the wild-type P450pyr were found to be 
capable of direct converting 4-fluorotoluene to its alcohol. Among all these 
investigated P450s, more than half of the P450pyr variants showed a very clean 
reaction and higher product concentration compare with P450pyr. A triple 
mutant N100S/F403I/M305Q (named as: P450pyr3M, Figure 5.1) was found to 
show the highest 4-fluorobenzyl alcohol concentration: 2.9 mM, which around 
10 fold compared to the wild-type P450pyr. The rate of production in 4 h is 
about 1.51 U/g, which is more than 600 times higher than p-cymene in 3 h. 
Therefore, this variant, P450pyr3M, was selected a promising catalyst for other 
benzylic hydroxylation.  
 
  
Figure 5.1 Hydroxylation of 4-fluorotoluene by recombinant E. coli (a) P450pyr, (b) P450pyr mutant 
N100S/F403I/M305Q (P450pyr3M).  
 
5.3.2 Cell Growth, Hydroxylation Activity and Protein Expression 
of E. coli (P450pyr3M) 
The cell growth and specific hydroxylation activities of the P450pyr3M at 




shown in Figure 5.2A, a cell density of 4.0 was researched after 10 h. Cells 
taken at different time points showed different hydroxylation activity towards 
4-fluorotoluene and the highest specific activity was observed for cells grown 
after 7 h, in the middle of exponential grow phase. Thus, harvested cells at this 
time point were used in the following biohydroxylation reactions. The SDS–
PAGE of cell-free extracts of E. coli P450pyr3M was prepared. As showed in 
Figure 5.2B, the P450pyr3M enzyme was clearly expressed in induced cells 
compare with non-induced cells, its expressing level was even higher than wild-
type P450pyr, thus enabling efficient and active biohydroxylation. 
 
Figure 5.2 Cell growth, specific activity and protein expression of E. coli (P450pyr3M). (a) 
Growth curve and specific activity for the hydroxylation of 4-fluorotoluene of E. coli 
(P450pyr3M). (b) SDS–PAGE of cell-free extracts of E. coli recombinant strains. 1: induced  
E. coli (P450pyr3M); 2: non-induced E. coli (P450pyr3M) as a negative control, and 3: induced 
E. coli (P450pyr) as a positive control. 
 
5.3.3 Biohydroxylation of Other Fluoro-Substituted Toluenes and 
Multi Fluoro-Substituted Toluenes with Resting Cells of 
Recombinant E. coli (P450pyr3M)  
After examining the cell growth and specific hydroxylation activities, E.coli 
(P450pyr3M) was investigated for biohydroxylation of 2- and 3-fluorotoluenes. 
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As shown in Figure 5.3, P450pyr3M exhibited very high hydroxylation activity 
(8.3 and 10.9 U g cdw-1) toward 2- and 3-fluorotoluenes. No by-product was 
formed in these two reactions, suggesting the excellent chemo- and benzylic 
hydroxylation selectivity.    
 
Figure 5.3 Hydroxylation of 2-fluorotoluene (a) and 3-fluorotoluene (b) by recombinant E. coli 
(P450pyr3M). Determined from 30 min biotransformation of 10 mM substrate with 4 g/cdw of 
cells at 30 oC and 300 rpm.  
 
Encouraged by the success in the biohydroxylation of single fluoro-substituted 
toluenes, P450pyr3M was used for the hydroxylation of more complicated 
substrates, multi fluoro-substituted toluenes. 3,4-difluorotoluene and 2,3,4,5,6-
pentafluorotoluene were selected since their hydroxylate products were 
important pharmaceutical intermediates, for example: 3,4-difluorobenzyl 
alcohol could be used for synthesizing DNA-dependent protein kinase 
inhibitors,317 while 2,3,4,5,6-pentafluorobenzyl alcohol is the key intermediate 
for the preparation of inhibitors of the kinase domain of vascular endothelial 
growth factor receptor-2.318 Although useful and important, so far no chemical- 
and bio-catalyst was reported capable of directed hydroxylation of these two 




comparative hydroxylation activity and conversion toward these two multi 
fluoro-substituted toluenes while wild-type P450pyr showed lower even lost its 
hydroxylation ability. These results confirmed that compare with wild-type 
P450pyr and other P450s, this P450pyr3M could accept the substrates 
containing bigger and stronger electron-withdrawing groups. To the best of our 
knowledge, P450pyr3M is the first enzyme for this type of hydroxylation to 
produce multi fluoro-substituted benzylic alcohols. 
 
Figure 5.4 Hydroxylation of 3,4-difluorotoluene (a) and 2,3,4,5,6-pentafluorotoluene (b) by 
recombinant E. coli (P450pyr3M). Determined from 30 min biotransformation of 10 mM 
substrate with 4 g/cdw of cells at 30 oC and 300 rpm.  
 
5.3.4 Biohydroxylation of Chloro- and Bromo-Substituted Toluenes 
with Resting Cells of Recombinant E. coli (P450pyr3M)  
Besides the fluoro-substituted toluenes, P450pyr3M was also found to catalyse 
the benzylic hydroxylation of ortho-, meta- and para-substituted chloro- and 
bromotoluenes at the methyl group giving the corresponding alcohols as the 
only product (Figure 5.5). Chloro- and bromo-substituted benzyl alcohols are 
two groups of useful intermediates. For example, 2-chlorobenzyl alcohol is an 




chlorobenzyl alcohol is used for producing coumarin monoamine oxidase B 
inhibitors320, 4-chlorobenzyl alcohol is an intermediate for advanced glycation 
end products (RAGE) Inhibitors.321 2-bromobenzyl alcohol is used for 
producing macrocyclic antagonists to the human motilin receptor,322 3-
bromobenzyl alcohol is an intermediate for synthesizing metabotropic 
glutamate receptor,323 and 4-bromobenzyl alcohol could be used for making 
vanilloid 1 receptor antagonists for the treatment of pain.324  
As showed in Figure 5.5, P450pyr3M also showed very high activity toward 
these chloro- and bromotoluenes compare to any other reported catalysts. For 
instance, P450pyr3M showed 13.0 U g cdw/L specific activity for 3-
chlorotoluene that is around 4.3 times higher than xylene oxygenase,109 and the 
rate of production of catalysed by P450pyr3M is about 1.8 U g cdw/L for 4 h 
which is 850 times higher than that (2.10 nanomoles product/minute) achieved 
by p-cymene for 3 h.108  
Interestingly, compared to the toluenes with a substitution at the 2- and 4-
position (ortho-, and para-position), the halo-toluenes with a substitution at the 
3-position (meta-position) were hydroxylated faster (higher specific activity and 
productivity). This preference is significantly different from other oxygenases, 
such as p-cymene monooxygenase and xylene oxygenase that both showed 4-
position favorite and no activity on 2-position substitution, indicating the unique 





Figure 5.5 Hydroxylation of 2-chlorotoluene (a) 3-chlorotoluene (b) and 4-chlorotoluene (c) by 
recombinant E. coli (P450pyr3M). Determined from 30 min biotransformation of 10 mM 













Table 5.2 Hydroxylation of single fluoro-, chloro-, bromo- and multi fluoro-substituted 
toluenes with resting cells of E.coli P450pyr3M and E.coli wild-type P450pyr 











P450pyr3M 8.3 3.1 62 




P450pyr3M 10.9 3.3 66 




P450pyr3M 7.6 2.9 58 




P450pyr3M 10.6 3.3 66 




P450pyr3M 13.0 3.5 70 




P450pyr3M 8.1 3.1 62 




P450pyr3M 10.8 3.3 66 




P450pyr3M 13.4 3.7 74 




P450pyr3M 8.2 3.1 62 






P450pyr3M 5.1 1.8 36 






P450pyr3M 2.0 1.1 22 
P450pyr NDc 0.1 2 
a activity is the specific activity determined for the first 30 min of the biotransformation, reaction 
were conducted with 10 mM substrate at 4 g cdw/L of E.coli expressing the P450pyr3M in 
potassium phosphate buffer (100 mM; pH 8) containing glucose (2%, w/v) at 30 oC and 250 
rpm for 30 min. b reaction were conducted with 5 mM substrate 10% DMSO at 8 g cdw/L of 
E.coli expressing the P450pyr3M at 30 oC and 250rpm for 4 h. Concentration and yield were 
determined by HPLC analysis. C ND: not determined. 
 
5.3.5 Biohydroxylation of 3-bromotoluene with resting cells of E. 
coli (P450pyr3M) 
To further improve the product concentration and test its stability, P450pyr3M 
was examined for hydroxylation at a higher substrate concentration, and 3-
bromotoluene was chosen as a model substrate. 25 mM of substrate was added 
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at the beginning, and product was quickly formed and reached 11.6 mM at 2 h 
and 16.5 mM at 4 h, finally 17.8 mM of product was produced after 12 h (Figure 
5.6). This is the highest concentration we have ever achieved in a simple flask 
condition by using E. coli (P450pyr) cells. According to our previous 
experiment results, both substrate and product inhibition are serious under this 
condition, which will prevent further improve the productivity.  
 
 
Figure 5.6 Time course of biohydroxylation of 25 mM 3-bromotoluene by resting cells of E. 
coli (P450pyr3M) (8.0 g cdw/L) in potassium phosphate buffer (100 mM, pH 8) containing 10% 
DMSO and glucose (2%, w/v) at 30 oC. 
 
5.3.6 Biohydroxylation of 3-fluorotoluene with resting cells of E. coli 
(P450pyr3M) and E.coli (P450pyr3M-GDH) 
Follow the same process described in chapter 3, E. coli (P450pyr3M-GDH) co-
expressing P450pyr3M monooxygenase and a glucose dehydrogenase (GDH) 




































same procedures described for E. coli (P450pyr3M). As illustrated in Figure 5.7, 
the new constructed recombinant with cofactor recycling system significantly 
improved the initial biohydroxylation activity up to 3 fold and also improved 
the final production yield about 20%.  
 
Figure 5.7 Time course of biohydroxylation of 25 mM 3-fluorotoluene by resting cells of E. 
coli BL21(DE3) (P450pyr3M with or without GDH) (8.0 g cdw/L) in potassium phosphate 
buffer (100 mM, pH 8) containing 10% DMSO and glucose (2%, w/v) at 30 oC. pRSFDuet-
P450pyr3M + pETDuet-Fdx/FdR (•); pETDuet-P450pyr3M/FdR + pRSFDuet-GDH/Fdx (■). 
 
5.3.7 Molecular Dynamics Simulations of P450pyr and P450pyr3M 
To shed light on the possible molecular basis of the stereo-chemical outcome of 
the reactions, in silico modelling and docking simulations were performed. 
Ramachandran plots were generated respectively for P450pyr and P450pyr3M 




Figure 5.8 Ramachandran plots for (a) P450pyr model before MD simulation (b) P450pyr 
model after MD simulation (c) P450pyr3M before MD simulation (d) P450pyr3M after MD 
simulation. All plots have > 90 % of residues within allowed regions, inclusive of the main 
residues of interest: the mutation sites at residues 100, 305, 403; and CYS366 which is bonded 
to the catalytic heme. Flexible glycine residues are depicted as triangles. 
 
As shown in Figure 5.8, more than 90% of residues to be within allowed regions. 
The well-structured residues included the main residues of interest: the mutation 
sites at residues 100, 305, 403; and CYS366, which was bonded to the catalytic 
heme. 
As can be seen from the generated P450pyr and P450pyr3M models, the binding 
pocket trunk of the P450pyr was predominantly hydrophobic, and it can be 
suitably characterized by two core hydrophobic residues Ile102 (shown in red) 
and Leu302 (shown in light green). Figure 5.9A showed the spatial relation 
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between these two core hydrophobic residues (Ile102, Leu302) and three 
residues Asn100, Met305, Phe403 in P450pyr model, while Figure 5.9B showed 
the spatial relation between the same core and the three mutated residues Ser100, 
Gln305, Ile403 in the triple mutant P340pyr3M model. 
 
Figure 5.9 Positional relation between the two core hydrophobic residues Ile102, Leu302, and 
the three residues of interest (100, 305, 403) in (A) wild-type P450pyr (B) triple mutant 
P450pyr3M. 
 
5.3.8 Molecular Modelling of Halo-Toluenes Docking in P450pyr 
and P450pyr3M 
Figure 5.10A and 5.10B showed the docked posture of 4-fluorotoluene in 
P450pyr and in P450pyr3M, respectively. The triple mutation N100S/M305Q/ 
F403I enlarged the binding pocket, where F403I removed the relatively bulky 
phenyl ring to allow the predominantly hydrophobic 4-fluorotoluene to dock 
with reduced hydrophobic-hydrophilic constrain between the nearby shorter 
residue Ser100 that was due to the mutation N100S. This was in contrast to the 
more constrained binding posture in the wild-type enzyme where 4-
fluorotoluene docked between the bulky phenyl ring of Phe403 and the longer 
117 
 
Asn100 residue in a position where the substrate methyl moiety was oriented 
further away from the activated heme-bound oxygen at 5.3 Å. Moreover, the 
mutation M305Q resulted in a more hydrophilic side chain Gln305, to mediate 
the binding posture of the predominantly hydrophobic substrate, such that the 
substrate methyl moiety was more directly oriented towards the activated heme-
bound oxygen at 3.8 Å. This explained the improved hydroxylation activity of 
P450pyr3M over the wild type when both were treated with 4-fluorotoluene, as 
experimentally observed. As an additional note, for both cases, the hydrophilic 
fluoro substituent was well oriented towards the hydrophilic region near 
ASP258 at the helix as shown. 
Additional docking simulations with 3-fluorotoluene and 4-bromotoluene were 
also established for P450pyr3M. As shown in Figure 5.10C and 5.10D 
respectively, with 3-fluorotoluene as substrate, the substrate methyl-C to heme-
O distance is 3.6 Å; while the corresponding distance is shorter at 3.3 Å with 4-
bromotoluene as the substrate. Comparing the docked postures of 3-
fluorotoluene and 4-fluorotoluene in the P450pyr3M, both postures were 
remarkably similar, indicating an overall optimal binding pose of fluoro-toluene 
substrates in P450pyr3M. The fluoro-substituent repositioning from para- to 
meta- position was sufficient to tilt the substrate methly-C closer to the heme-




Figure 5.10 Substrate-enzyme binding pose. (a) Wild-type P450pyr with 4-fluorotoluene (b) 
P450pyr3M with 4-fluorotoluene, (c) P450pyr3M and 3-fluorotoluene, and (d) P450pyr3M and 
4-bromotoluene. Mutation sites are illustrated in yellow. The distance (in angstrom) between 
the methyl-C atom of substrate and the heme-oxygen atom is denoted by a red dashed line. 
 
For 4-bromotoluene, steric repulsion existed between the much larger bromo-
substituent and the hydrophilic region near ASP258. The enlarged binding 
pocket space between Ser100 and Ile403 allowed a reorientation of 4-
bromotoluene to avoid the aforementioned steric repulsion, while subject to 
hydrophobic-hydrophilic constrain mediated by Gln305. The resulting docked 
posture had substrate methly-C to heme-O distance reduced to 3.3 Å (Figure 
5.9D). Thus the preference of inserting an O-atom into a halo-toluene substrate 
was improved with mutations over the wild-type enzyme, along with meta-
substituent positions over para-substituent positions (for the same halo group); 
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and bromo-substituents over flouro-substituents (for the same substituent 
position). Overall, the in silico modelling and docking simulations can help 
account for the higher hydroxylation activity in the mutant enzymes with the 
differences in halogen substituent choices. 
An alternative appreciation of the effect of the triple mutation 
N100S/M305Q/F403I on the substrate binding postures was presented in 
Figures 5.11. They depicted the surface representation of the docked substrates 
for the P450pyr and P450pyr3M. The binding posture of 3-fluorotoluene in the 
P450pyr with the narrower binding pocket space was illustrated in Figure 5.11A, 
in contrast to that of same substrate in the widened pocket space of the mutant 
enzyme (Figure 5.11B). In Figure 5.11C, the docked posture of 3-fluorotoluene 
in the mutant enzyme was remarkably similar to that for 4-fluorotoluene (Figure 
5.11B), where in both cases, the hydrophilic fluoro-substituent was well 
oriented towards hydrophilic region near ASP258 (represented as light pink 
patch). A significant change in docked posture occured for 4-bromotoluene as 
shown in Figure 5.11D where steric hindrance between the bromo-substituent 
and the region near ASP258 forced the substrate to re-orientate along the 
increased space near Ser100-Ile102, thereby reducing the methyl-C to heme-O 




Figure 5.11 Surface representation of enzyme-substrate binding pose (a) 4-fluorotoluene in 
wild type P450pyr (b) 4-fluorotoluene in triple mutant P450pyr3M (c) 3-fluorotoluene in 
P450pyr3M (d) 4-bromotoluene in P450pyr3M. Mutated residues are shown in yellow.  
 
5.4 Conclusions  
In summary, total 29 recombinants E. coli P450pyr variants as well as wild-type 
P450pyr were applied for the biohydroxylation of fluoro-substituted toluene. 
One triple mutant, P450pyr3M, was discovered as the first enzyme with 
excellent activity and chemo- and regioselective for the benzylic hydroxylation 
of fluoro-, chloro- and bromo-substituted toluenes. This enzyme also worked 
well with the substrates containing electron-withdrawing groups, such as 3,4-
difluorotoluene and 2,3,4,5,6-pentafluorotoluene. These hydroxylation 
reactions provide a simple access to the corresponding halo-benzyl alcohols, 
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which are useful pharmaceutical intermediates and cannot be prepared thus far 
by using other enzymatic or chemical systems. In silico modelling and substrate 
docking provided with some insight into the influence of three important amino 
acid mutations of the engineered P450pyr mutant on the enhanced activity. The 
obtained information and knowledge is useful for further engineering of 







 Chapter 6. Summary and recommendations 
6.1 Summary 
Regio- and enantioselective hydroxylation is a useful but challenging reaction 
in classic chemistry. Alternatively, nature finds a useful solution for this type of 
reaction by using monooxygenases as catalysts. Many monooxygenases have 
been used for the hydroxylations of special types of substrates and cytochrome 
P450 monooxygenases form the largest sub-family. Nevertheless, there are still 
many problems left that limit the further application of P450 monooxygenases 
for regio- and enantioselective hydroxylations, such as the narrow substrate 
scope and unsatisfied activity and selectivity toward a given non-natural 
substrate. In this thesis, we used the directed evolution method to develop a set 
of novel P450 monooxygenases with better regio- and/or enantioselectivity, 
new substrate acceptance and improved activity for certain targeted 
hydroxylations.  
Firstly, a terminal selective P450pyr was successfully engineered through 
directed evolution for the subterminal hydroxylation of alkanes with excellent 
enantioselectivity. A novel colorimetric HTS assay was developed for the 
measurement of both the regioselectivity and the enantioselectivity of a 
hydroxylation reaction. By using this HTS assay and ISM, sextuple-mutant 
P450pyrSM1 was created for the hydroxylation of n-octane to give (S)-2-
octanol with 98 % ee and > 99% subterminal selectivity. It is a breakthrough in 
the directed evolution: 1) the engineered P450pyr mutant is the first enzyme for 
the highly selective alkane hydroxylation. 2) the generation of P450pyrSM1 is 
the first example of the full alteration of enzyme regioselectivity and 
123 
 
simultaneous establishment of high enantioselectivity by directed evolution. 3) 
the new developed colorimetric HTS assay could be generally applicable to the 
discovery of other types of catalyst for regio- and enantioselective 
hydroxylations.  
Secondly, this P450pyr was successfully engineered for highly regioselective 
terminal hydroxylation of n-butanol. Based on a surrogate substrate-based 
colorimetric HTS assay, in two rounds of evolution, P450pyr single mutant 
I83M and double mutant I83M/I82T were generated to show excellent terminal 
regioselectivity for the hydroxylation of n-butanol. This is the first report of this 
hydroxylation by chemical or enzymatic method. This is also a unique example 
of evolving a monooxygenase to switch the substrate acceptance from a 
hydrophobic to hydrophilic compound.  
Thirdly, an engineered P450pyr mutant (P450pyr3M) was discovered as the 
best catalyst for benzylic hydroxylation of single and multiple fluoro-
substituted toluenes. This mutant also showed a broader substrate range, higher 
activity and higher conversion for the hydroxylation of chloro-, and bromo-
toluenes compare with all the reported chemical- and bio-catalysts. These 
hydroxylations provide a simple access to the corresponding halo-benzyl 
alcohols, which are useful pharmaceutical intermediates.  
In conclusion, this thesis demonstrated successful examples of using directed 
evolution to create new enzymes with better catalytic performances, including: 
better regio- and/or enantioselectivity, new substrate acceptance and improved 
activity for the green, clean and sustainable production of chemicals and 
pharmaceuticals. Molecular modelling on the hydroxylations of different 
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substrates with P450pyr and P450pyr mutants gave some insights on the 
unsderstanding of the roles of several key amino acid mutations for the better 
catalytic performances. This information could be useful for further evolution 
of P450pyr to achive high catalytic performance for other desired 
hydroxylations or oxidations.   
 
6.2 Recommendations 
The further development of biocatalysts for the green and sustainable 
production of chemicals could focus on the following aspects. 
Besides activity, substrate scope and selectivity, the P450pyr stability could also 
be improved through directed evolution. Except the ISM method used in this 
thesis, other methods such as: epPCR and DNA shuffling could also be used to 
improve the enzyme’s stability. Besides, based on the crystal structure and the 
knowledge of enzyme stability, we may rationally change some literature-
known key residues which located not in the activity site but at the enzyme 
surface to improve the enzyme stability. With increased stability, the P450pyr 
enzyme would have longer survival times, improved reaction kinetics and more 
tolerant of the destabilising effects of mutations.     
Besides ISM, other methods such as synthetic biology, whereby increasingly 
large sequences of DNA can be synthesised de novo, could be used to further 
engineer P450pyr with novel functions. Based on other protein sequence-
structure-function relationships, more judicious strategies could be used to 
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design (for binding, specificity and active site modelling) the best amino acid 
sequence to develop novel biocatalysts that are both highly active and robust. 
The regio- and enantioselective HTS assay was proven to be very simple, fast 
and powerful in our study. This method can be further applied in P450pyr 
engineering for the regio- and enantioselective hydroxylation of other more 
useful substrates, such as steroids, which have important clinical applications 
but industrial productions are limited due to complexity of the molecules. The 
knowledge of the P450pyr and P450pyr-substrate structures will provide useful 
information on possible amino acid sites that become important for substrate 
binding, which could be employed as a basic for the screening of new substrates. 
What’s more, as we mentioned several times in this thesis, a few amino acid 
residues in the active site have been repeatedly observed to play key roles during 
substrate binding and regio- and enantioselectivity controlling. ISM on these 
sites would save a lot of mutant library generation and HTS screening work.  
Although the new developed HTS assays work well in the experiment, these 
assays still suffers from the low product concentration at the end of reaction. 
This is possibly because of low cell amount and mass transfer inhibition of 
substrate molecules in each well. In order to generate more cells in the 96-deep 
well plate, rich medium such as TB or SOC could be used, while the substrate 
mass transfer problem could be solved by treatment using solvent, detergent, 
freezing and thawing, both method could further increase the biohydroxylation 
conversion in the HTS.   
Several organisms and enzymes have been discovered to produce n-butanol 
through hydroxylation of butane. Co-expression of butane monooxygenase and 
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P450pyr monooxygenase could be used to attempt to produce 1,4-butanediol 
directly from butane in a one pot reaction. This can be done by either 
transforming the P450pyr, Fdx and FdR gene into organisms that can convert 
butane to butanol or coupled two permeabilised microorganisms.  
The productivity of P450pyr and its mutants were still not good enough for 
practical application. The P450-catalysed biohydroxylations suffer from the 
immiscibility of substrate and/or substrate and product inhibitions, and thus the 
productivities are generally lower than other types of enzyme-catalysed reaction. 
To enhance the biohydroxylation productivity, several biphasic systems such as: 
aqueous/ organic biphasic system, aqueous/resin biphasic system and 
aqueous/ionic liquid biphasic system could be used. Besides, the cell grow 
condition, proteins (P450, Fdx and FdR) expression level/ratio and substrate 
concentration could also be studied. What’s more, the expressing E.coli strain, 
dissolved oxygen content, IPTG and ALA concentrations also have to be 
optimised to achieve a higher productivity.  
Finally, in order to understand the biochemistry mechanism of energy transfer 
within P450pyr system, it could be necessary to crystallise its redox factors: 
ferredoxin (Fdx) and ferredoxin reductase (FdR). The X-ray structure of Fdx 
and FdR together with P450pyr, would provide an integral structure-function 
relationship of P450pyr complex system, which could be useful for the 
improvement of P450pyr activity and productivity, as well as developing a 
P450pyr-Fdx-FdR fusion protein for enzyme immobilization. Besides, it would 
also be interesting to crystallise P450pyr mutants together with their substrates. 
These structures would greatly enhance our understanding of the structure-
function relationship between P450pyr and substrates, and these structures 
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could also provide an insight into the connection between selectivity and key 
residues in P450pyr active pocket, which would be very useful and helpful to 
further improve the design of new amino acid mutations within the binding 
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